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ABSTRACT 
Statin drugs are a very commonly prescribed medication, and their most common side effect is 
some degree of skeletal muscle myopathy. Unfortunately, this side effect is more likely/severe in 
statin users who are also exercisers. Purpose: To examine the previously unaddressed interactions 
of statin treatment with novel vs. accustomed exercise, as well as to examine cellular markers of 
the stress response—heat shock proteins (Hsps)—and apoptosis—activated caspases. Methods: 
C57 mice were treated with daily cerivastatin (1/mg/kg/day) or saline for two weeks, with/without 
concomitant wheel running (RW) (Novel & Sedentary groups). Additional groups also performed 
two weeks of RW activity prior to the initiation of statin treatment (Accustomed groups). RW 
activity was tracked daily, and hindlimb plantarflexor maximal force and fatigue was measured at 
the end of the intervention. Hsp25, αB-Crystallin, Caspase-3, and Caspase-9 were measured by 
western blot, plasma creatine kinase (CK) was assessed by activity assay. Results: Statin treatment 
did not significantly impact RW activity, however both sedentary and novel-exercise groups 
showed decrements in muscle force and fatigability with statin treatment. The effect on maximal 
force was more severe in the novel-exercise group, while accustomed exercise mice were protected 
from this decrement. Plasma creatine kinase levels did not correlate with functional outcomes. No 
significant effect of statin treatment was found for hsp25 or αB-Crystallin expression, though both 
proteins were increased by both the novel and accustomed exercise interventions. A significant 
injection by activity interaction was found for active caspase-9 expression, with statins increasing 
expression in the sedentary and novel groups, but decreasing expression in the accustomed groups. 
Active caspase-3 was not detectable in any group. Conclusions: These results indicate that 
exercise training prior to statin treatment can protect against myopathy, rather than exacerbate it, 
as seen with novel exercise. Additionally, accustomed exercise was able to reverse statin 
treatment’s activation of caspase-9, though the physiological significance of this is unclear, as the 
lack of caspase-3 expression indicates that apoptosis did not in fact occur. An upregulation in Hsp 
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expression with exercise may have contributed to the preservation of muscle force and decreased 
caspase-9 expression in the accustomed groups. 
iv 
 
ACKNOWLEDGMENTS 
Like most extended labors of sleep-deprived work and writings, there are always those who 
aid in the journey, and I cannot take full credit for what I’ve accomplished here. First and foremost 
I would like to thank my mentor, Dr. Kimberly Huey, who helped me in the process of 
transitioning from a Bachelor of Arts grad to a basic sciences PhD student, and who guided and 
encouraged me in pursuing my own avenues of interest and research. I would not be where I am 
today if she had not accepted me into her lab and challenged me to come up with my own ideas 
and approaches. Those reading this dissertation should also be especially thankful to Kim, as she 
provided a great deal of revision input and helped bring the language back to a simpler tone when 
my rhetoric background tried to run away with things. 
Another sincere thanks to Tracy Baynard, who occasionally provided some much-needed 
manpower when my lack of lab-mates and undergrad assistants became problematic, and who—
more importantly—provided a voice of experience when I needed it, and the voice of ―get moving 
on it!‖ when I needed that too. 
Of course, no dissertation happens without the committee,  and I need to thank Bo Fernhall, 
Ellen Evens, Marni Boppart, and Rodney Johnson, who were not only kind enough to serve as 
members, but also to provide guidance and field questions that would normally be left to the 
research advisor. I am especially thankful to Ellen Evans, who was kind enough to serve as my 
committee chair and bear the brunt of the Administrative Process, even while knowing that the 
cellular-level discussions of the final manuscripts may do her grievous mental harm. 
Additionally, there are my family and my friends, who supported me in my choice to be a 
―professional student‖. Especially Erica, who supported and helped me even when our own 
v 
 
individual graduate career loads made it difficult. And also especially Harry, who helped keep me 
sane on a daily basis. 
Finally, the American Heart Association and the National Skeletal Muscle Research Board deserve 
special thanks, as without their financial support this project may never have happened. 
vi 
 
TABLE OF CONTENTS 
 
GLOSSARY OF KEY TERMS ....................................................................................................................................... vii 
INTRODUCTION .............................................................................................................................................................. 1 
SPECIFIC STUDY AIMS ...................................................................................................................................................... 3 
SIGNIFICANCE ................................................................................................................................................................... 4 
CHAPTER 1: LITERATURE REVIEW ......................................................................................................................... 6 
CHAPTER 2: EXPERIMENTAL METHODS .............................................................................................................. 29 
CHAPTER 3: STATINS AND MUSCLE FUNCTION ................................................................................................. 39 
CHAPTER 4: CELLULAR MECHANISMS ................................................................................................................ 53 
APPENDIX ....................................................................................................................................................................... 81 
CURRICULUM VITAE .................................................................................................................................................. 97 
 
vii 
 
 
GLOSSARY OF KEY TERMS 
Caspase-3: Cysteine Aspartic acid Protease 3. Important to the execution of cellular apoptosis, 
especially so in skeletal muscle, as it is likely the rate-limiting protease in actinomyosin 
complex breakdown. 
Caspase-9: Cysteine Aspartic acid Protease 9. An initiator caspase involved in mitochondrially 
mediated apoptosis, and an activator of Caspase-3. 
Cerivastatin (Baycol): Synthetic statin marketed by Bayer. Withdrawn from the market in 2001 
due to an unusually high incidence of fatal rhabdomyolysis.  
Creatine Kinase (CK): Enzyme catalyzing the conversion of creatine to phosphocreatine, 
expressed at especially high levels in striated muscle.  Damage to muscle membranes 
allows leakage into the blood, leading to CK’s use as a marker of muscle damage. 
Familial Hypercholesterolemia: Genetic disorder characterized by exceptionally high LDL 
levels. Typically due to mutations in the genes encoding for LDL receptors or 
apolipoprotein B. 
F-Box Protein: Family of proteins containing one or more F-box structural motifs. Importantly, a 
component of a ubiquitin proteasome complex (SCF complex) which targets proteins for 
ubiquitin-tagging and subsequent degradation in the proteasome. F-box proteins provide 
ligase specificity to this complex. 
GTPase: Large family of enzymes able to bind and hydrolyze GTP that are involved in cell 
signaling and protein synthesis. Parent family to the Ras superfamily of small GTPases. 
Small GTPases typically require prenylation before participating in cell signaling. 
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Heat Shock Protein (Hsp): Family of highly conserved proteins involved in both basal cellular 
processes and cellular protection and stress response. Both protective against and activated 
by a wide variety of cellular stressors, such as inflammation, oxidative stress, toxins, and 
exercise. 
Myoblasts: Embryonic progenitor cell that can develop into a myocyte.  
Myopathy: General term for muscle disease leading to weakness or other dysfunction. 
Myosin Heavy Chain (MHC): Component of the myosin II protein responsible for the 
development of contractile force in muscle. Different MHC isoforms demonstrate differing 
contractile characteristics, and are therefore a common method of fiber-typing. 
Myotubes: Developing skeletal muscle cells grown in culture, formed by the fusion of multiple 
myoblasts. So named due to their tubular appearance, which is quite distinct from 
myoblasts. 
Prenylation: Attachment of one or more lipid groups (i.e. a terpenoid) to a protein. Affects the 
lipophilic properties of the protein, importantly, impacts membrane attachment. 
Rhabdomyolysis: Potentially fatal condition of uncontrolled muscle breakdown which releases 
muscle cell content into the bloodstream. Several released compounds have toxic effects 
outside the muscle, and cause disruptions in renal function, electrolyte balance, and blood 
clotting. 
Statin: HMG-CoA reductase inhibitor. Class of drugs used in the reduction of blood cholesterol 
via the inhibition of the mevalonate pathway at HMG-CoA reductase, though their 
reductions in cardiovascular disease risk go beyond these effects. Some degree of 
myopathy or myalgia is the most common side effect. 
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Squalene: Downstream compound of the mevalonate pathway necessary to the biosynthesis of 
cholesterol. Squalene’s position in the pathway downstream of most intermediate 
compounds but upstream of cholesterol positions it as a useful compound for investigating 
the impact of cholesterol reductions (by inhibiting squalene synthase) independent of 
statins. 
Terpenoids: Extremely large group of lipid compounds. Important to the current topic due to their 
being produced via the mevalonate pathway and their importance to the process of 
prenylation. 
Ubiquinone: Also known as coenzyme Q10. Involve in the electron transport chain and aerobic 
respiration, and therefore mostly expressed in the mitochondria. Ubiquinone biosynthesis 
occurs via the mevalonate pathway. 
Ubiquitin Proteasome: Also known as the 26S proteasome. Proteasome responsible for the 
breakdown of proteins that have been ubiquitin-tagged by the SCF-complexes (see F-box 
protein). 
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INTRODUCTION 
 HMG-CoA reductase inhibitors (statins) are a common and effective pharmaceutical 
treatment for elevated blood cholesterol levels and high coronary heart disease risk. While they are 
a safe class of drugs overall, they do have side effects, the most common among these being some 
degree of skeletal muscle myopathy or myalgia. The risk for these side effects has not been 
conclusively determined, however it is judged to range between 1 and 10% of all statin users. The 
primary concern of the current work is that this risk is considerably elevated in those statin users 
who are also exercisers, reportedly as high as 25%. Unfortunately, while the mechanisms behind 
statin-associated myopathy in general are not well understood, the mechanisms involved in this 
exacerbation by exercise are neither well understood nor well-examined. 
The vast majority of the available literature has examined the response to a single bout of 
exercise after a period of statin treatment, and has therefore examined a statin-potentiated exercise-
damage response, and not an exacerbation of statin-associated myopathy by exercise. However, the 
true distinction between these two effects is impossible to discern based on current literature, as it 
is currently unknown whether exercise-exacerbated myopathy is the result of cumulative 
exaggerated damage responses to single exercise bouts, exercise-induced exacerbation of damage 
pathways active in sedentary statin-treated muscle, or exercise-induced activation of an otherwise 
dormant statin-induced damage pathway. In any case, the majority of this literature has not been 
mechanistic in nature, and examinations of the actual mechanisms involved in statin/exercise 
interactions is extremely sparse.  
 Unfortunately, investigation of this interaction is further complicated by the adaptations 
that occur in skeletal muscle in response to an exercise bout or to exercise training. As noted, the 
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majority of the prior literature examines the response to a single exercise bout, and there exists 
only one prior study investigating multiple exercise bouts. None of these studies have allowed 
exercise accustomization to occur prior to the initiation of statin treatment. Therefore, since all 
prior research has utilized an exercise stimulus that is novel—and therefore unusually damaging so 
far as the subject is concerned—none of this prior research accounts for the adaptations that occur 
in muscle in response to as little as a single exercise bout. As a result, this research is not 
necessarily translatable to an exercise-trained individual, or even to an individual who might not be 
considered ―trained‖, but who does not change their physical activity routines after beginning 
statin treatment.  
Finally, an additional issue exists in the quality of the damage measures used to assess 
myopathy. Literature examining exercise and statin interactions commonly use blood creatine 
kinase (CK) in the examination of damage responses, and only a few studies have examined 
muscle damage though histological or other methods. Creatine kinase is not a reliable or repeatable 
measure of exercise-induced muscle damage, and the use of CK is especially problematic in 
examining the combination of exercise and statins because CK levels have also been repeatedly 
shown to be an insensitive marker of statin-associated myopathy. Therefore the interactions of 
statins and exercise have commonly been examined through a measure that is a poor marker for 
both components of the interaction individually, and therefore cannot be expected to be a reliable 
measure of them in combination. 
The current work seeks first to address the issue of exercise training prior to the initiation 
of statin treatment, and whether statins’ interaction with accustomed exercise is the same as that 
with novel exercise. Furthermore, in addition to increasing the overall validity of the study, the use 
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of a functional and reliable measure of muscle damage—force-production ability—allows the 
examination of CK’s utility as a measure for exercise/statin interactions.  
Finally, mechanisms of the exercise/statin interaction will be examined. Specifically, the 
effect of statin treatment on skeletal muscle heat shock protein expression has not yet been 
investigated, though heat shock protein expression presents a potential mechanism affecting the 
interactions between statins and repeated exercise. Additionally, markers for apoptosis will be 
examined, as there is strong in vitro evidence indicating that statins are able to initiate apoptosis in 
numerous cell types, including skeletal muscle cells. In vivo research has indicated that skeletal 
muscle apoptosis does not in fact occur, however this has not been examined under the potentially 
more damaging condition of combined statin and exercise treatments. 
 
SPECIFIC STUDY AIMS 
Aim 1: Examine the effects of accustomed exercise versus novel exercise on statin-induced 
myopathy, and how either exercise treatment compares to sedentary mice. 
Hypothesis: We hypothesize that two weeks of running wheel activity prior to the commencement 
of statin therapy will be protective against statin-induced myopathy during the subsequent two 
weeks of concomitant wheel-running and statin treatment. We expect the sedentary, statin-treated 
mice to show decrements in maximal force production ability, and that the novel-exercise mice 
will show an even greater deficit. 
 
Aim 2: Examine the validity of using CK measures as a marker for statin-associated 
myopathy under both sedentary and exercise conditions. 
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Hypothesis: We expect that statin treatment may increase blood CK levels in the sedentary and 
novel-exercise mice at the level of a statistical main-effect. However, we do not expect significant 
within-subject correlations to exist between CK levels and functional muscle measures, which 
would contraindicate CK’s sole use as a clinical measure for statin-associated myopathy. 
 
Aim 3: Examine molecular markers for apoptosis (caspase-3, caspase-9) and the stress 
response (Hsp25, αB-Crystallin) under all combinations of statin and exercise treatment.  
Hypothesis: We expect two weeks of running wheel activity to upregulate heat shock protein 
expression in the novel-exercise mice, and for this upregulation to be associated with the 
preservation of muscle function during statin treatment. Further, we hypothesize that statin 
treatment in the novel-exercise mice will block this upregulation. Finally, while apoptotic markers 
are not expected to be elevated in the sedentary mice, we hypothesize that the combination of 
novel exercise and statin treatment may lead to the expression of caspase-9 and caspase-3 in 
skeletal muscle. 
SIGNIFICANCE 
While statins do not have unusually high incidences of side effects, the large population of 
individuals on statin therapy lends considerable weight to any advancement that can decrease the 
incidence of harmful side effects and improve quality of life. The current work seeks to contribute 
to such advancements through several avenues. The first is to address the issue of novel versus 
accustomed exercise and statin treatment. This topic has not previously been examined, but it 
potentially presents a subject of great clinical importance. If it were discovered that certain 
exercise modalities or scheduling regimens are able to prevent or alleviate the occurrence of statin-
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associated myopathy clinicians would have an entirely new set of tools with which to address 
exercise and statins’ deleterious interactions. This research makes the first inroads towards 
developing a body of research to hopefully make such interventions possible. 
Secondly, as previously noted, investigations into the mechanisms behind exercise and 
statins’ interactions are extremely limited. The current investigations of heat shock protein and 
caspase expression will expand the available mechanistic data on novel exercise, as well as provide 
the first mechanistic data in the examination of statins and accustomed exercise. While it may not 
necessarily be required in the development of the type of exercise regimens mentioned above, it is 
unlikely that any improvement in statin-associated myopathy will be achieved through 
pharmacological, nutritional, or similar means without a further understanding of the mechanisms 
involved. 
Finally, a more society-based, less scientific, and perhaps overly optimistic goal of the 
current work is to encourage further research into this remarkably barren area. Ultimately, a 
mature literature base covering diverse combinations of exercise interventions and cellular 
mechanisms is likely to be needed before any significant breakthroughs can be made. As the 
current literature base is far from being well developed, there is little expectation that the current 
work will lead to any such breakthrough. Therefore this study was conceived with the intention of 
challenging the prior research designs all utilizing similar exercise interventions and measures in 
the hope that others will take an interest in expanding this area of research. 
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CHAPTER 1: LITERATURE REVIEW 
Statin-Associated Myopathy and its Exacerbation with Exercise* 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
* This manuscript has been previously published and can be accessed by the below reference. Its 
current use has been permitted by the original publisher. 
 
Meador, B.M., Huey, K.A. Statin-Associated Myopathy and its Exacerbation with Exercise. 
Muscle and Nerve 2010;42:469-479.  © Wiley-Blackwell 
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INTRODUCTION 
 HMG-CoA reductase inhibitors (statins) are currently the most effective lipid-lowering 
drugs available. Due to their high efficacy and the fact that they are generally very well-tolerated, 
they are widely used, with over 100 million prescriptions filled for over 14 million patients in the 
year 2004 
1
. Despite this, many consider statins to still be under-prescribed 
2-6
, and their use is 
expected to continue to grow alongside the increasing elderly population and ongoing discoveries 
of pleiotropic effects of statins 
1
.  
Overall, statins are a relatively safe family of drugs. However, statin therapy significantly 
elevates the risk of myopathy, which can range from muscle weakness, aches, and fatigue to 
rhabdomyolysis. It has been estimated that rhabdomyolysis affects as many as 0.1% of all statin 
users, and the occurrence of general myopathies has been estimated to range from 1-10% 
1,7-9
. 
While this presents a relatively low risk of complications and almost certainly does not outweigh 
the benefits in cardiovascular risk modification, the sheer number of patients prescribed statin 
medication leads to a large absolute number of myopathic complications. Additionally, while low-
density lipoprotein (LDL) levels and cardiovascular disease risk decrease with higher statin doses 
10
, the risk of statin-associated myopathy may increase in a dose-dependant manner 
11,7
. 
Unfortunately, this puts lipid profiles and muscle function at odds, and considering that the 
majority of adults are sedentary 
12
, it is not surprising that the recommended doses favor optimal 
lipid profiles over optimal muscle function 
10,13
. 
The risk/benefit analysis of statin therapy and dosing is further complicated by the common 
finding that exercise seems to increase the risk for statin-induced muscle myopathy. The 
prevalence of myopathy dramatically rises to as high as 25% among statin users who are also 
exercisers 
1,14,13
, and may be over 75% in statin-treated athletes 
15
. Clearly, this presents an even 
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greater paradox, as certainly it is not desirable for physical inactivity to ever be a necessary 
prerequisite to successful and complication-free statin treatment.  Numerous studies have shown 
that physically active individuals have a significantly reduced risk of cardiovascular disease as 
compared to less active individuals 
16-21
, therefore, the potentially antagonistic effects of statin 
therapy and physical activity on muscle function present a challenge in achieving the best possible 
reductions in cardiovascular risk. Identification of the circumstances in which physical activity 
exacerbates statin-induced myopathy and the mechanisms through which these effects are 
mediated is needed to overcome this antagonism and appreciate the full benefits of both statin 
therapy and physical activity.  
Several reviews address the general issues of statin-related myopathies 
1,22,23,13
, and thus 
this review focuses primarily on the exacerbation of myopathy incidence or severity by the 
combination of physical activity and statin treatment. Our goal is to outline the relevant research 
and to highlight topics in which further examination is needed in this sparsely researched area.  
 
MECHANISMS OF STATIN-INDUCED MYOPATHY 
The mechanisms behind statin-induced myopathy are currently not well understood. 
Furthermore, whether the pathways behind myopathy in sedentary individuals are also the 
pathways responsible for exacerbated myopathy with exercise is currently unknown. However, in 
the absence of mechanistic literature regarding statins and exercise, pathways implicated in 
sedentary myopathy present a logical starting point for investigating exercise interactions, and in 
the interest of highlighting directions for future research we have made note of those pathways 
which may be candidates for exercise exacerbation. 
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Statins have been shown to induce apoptosis in numerous cell types, including cardiac 
myoctyes, smooth muscle cells, pericytes, and cancer cells 
24-33
. While these apoptotic actions have 
indicated a potential role for statins in anti-cancer treatments 
28
 and the attenuation of cardiac 
hypertrophy 
34
, in skeletal muscle they may lead to myopathy. Specifically, statin therapy has been 
shown to induce apoptosis in myotubes and myoblasts, as well as differentiated primary human 
skeletal muscle cells 
35-38
.  
Multiple pathways exist to activate apoptosis in skeletal muscle, both intrinsic to the 
muscle fiber itself—such as elevated intracellular calcium or reactive oxygen species—and 
extrinsic—such as Tumor Necrosis Factor-alpha signaling. Additionally, it has been shown that 
statin-induced apoptosis proceeds through the caspase-dependant pathway, as it leads to an 
increase in caspase-9 and caspase-3 activity 
35,38
. In muscle, the ubiquitin-proteasome (UP) system 
cannot break down actinomyosin complexes. However, caspase-3 is likely the rate-limiting 
protease for myofilament release, and as such is strongly implicated in both accelerated contractile 
protein breakdown 
39,40
 and muscle weakness 
41
. 
Unfortunately, the in vitro evidence for statin-induced apoptosis has not been confirmed in 
vivo, and no studies have investigated if exercise exacerbates the potential apoptotic effects of 
statins. To date, apoptotic markers have only been quantified in two studies. In 11 
hypercholesterolemic clinic patients with statin-associated myopathy no evidence of increased 
apoptosis was observed in several apoptotic markers including TUNEL staining, Bax, Bcl-2, and 
caspase-3 
42
.  In rats receiving a high dose of cerivastatin (1mg/kg/day) no differences in activated 
caspase-3 expression were observed following 14 days of statin treatment 
43
. While this 
intervention corresponds temporally to the ~2-week time-points at which statin-induced damage 
has been confirmed 
44,43
, the authors suggest their measurement of activated caspase-3 at 24h post-
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statin administration may have missed a potential rise in active caspase-3, since it is an early 
measure of apoptosis 
43
. Information on the temporal relationship between muscle biopsies and 
statin administration in the aforementioned human patient study was not given. Whether statins 
induce elevations in caspase-3 activity in vivo prior to the previously examined 24-hour time-point 
is currently unknown, and evidence is lacking regarding the mechanism through which statins may 
activate apoptotic pathways in muscle fibers. 
Another possible contributor to statin-associated myopathy is a reduction in muscle 
membrane fluidity due to reduced cholesterol content, which has been a concern with other lipid-
lowering medications such as niacin and clofibrate 
45,46
. This would also help explain an elevated 
risk with exercise, in which the muscle can be exposed to high levels of mechanical loading and 
stretch. However—despite being the major clinical target of statin prescription—reductions in 
cholesterol levels do not appear to be a direct contributor to myopathy. Inhibition of the cholesterol 
synthesis pathway downstream of HMG-CoA—by inhibition of the enzyme squalene synthase—
does not trigger myopathy 
47,48
, as would be expected if a shift in membrane composition was a 
major contributor to myopathy. These data also indicate that at least some of statins’ myotoxic 
effects are downstream of mevalonate, but not of squalene synthase (Figure 1.1). However, since 
membrane composition or fluidity has not been examined under the additional stress of exercise, it 
is possible that the increased mechanical load/stretch imposed on a muscle fiber with exercise 
would bring to light subtle shifts in membrane composition or reductions in fluidity that could lead 
to damage.  
One of the possible mediators fitting the requirement of being upstream of squalene 
synthase but downstream of mevalonate are the terpenoids, and indeed it has been consistently 
shown that reduced terpenoid levels induce apoptosis in various cell types 
24,34,28-30,35,31,36,32,33
. 
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Terpenoids are a highly diverse class of lipid molecules which are precursors to many compounds, 
and—importantly—can also modify proteins by adding lipid groups in a process called 
prenylation. Several studies have demonstrated that decreased geranylgeranyl pyrophostate and 
farnesyl pyrophosphate levels—primary precursors to terpenoid production—result in the expected 
downstream effect of terpenoid depletion and can, contribute to statin-induced apoptosis 
30,31,36,33
. 
Among the proteins affected by reductions in prenylation would be the important GTPases Ras, 
Rho, and Rac, which require prenylation by terpenoids before membrane association, where they 
participate in cell signaling 
49,50
. If prenylation is inhibited, GTPases will remain cytosolic and 
inactive
51,52
 (Figure 1.1).  Therefore, as GTPases are involved in a wide range of cell signaling 
pathways, a reduction in terpenoid levels has the potential to impair cell signaling in a wide variety 
of pathways, including apoptotic and MAPK signaling. Since the MAPK pathway is rapidly 
activated by muscle contraction 
53
, the effects of decreased terpenoids on this signaling pathway 
may present another candidate mechanism for exacerbation of statin-induced myopathy with 
exercise (Figure 1.2).  However, it should be noted that these results are often correlative and not 
mechanistic in nature. Additionally, the pathways involved are highly dependent on cell type, and 
have not yet been examined in differentiated skeletal muscle. 
Alternatively, it has been theorized that downregulation of the mevalonate pathway and 
reductions in terpenoid availability could lead to a reduced muscle content of ubiquinones (Figure 
1.2). However, this theory is not well-supported by the literature, as both in vitro 
35,54
 and in vivo 
data has been inconsistent 
42,55-57
. Furthermore, in vitro data has indicated that the changes that 
may occur in ubiquinone content do not correlate with an increase in apoptosis 
35
. Currently, the 
data on ubiquinone levels is deemed insufficient to justify the recommendation of ubiquinone 
supplementation to statin patients as a therapy to reduce myopathy 
55,58
.  
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FIGURE 1.1: MEVALONATE PATHWAY 
 
Figure 1.1: Simplified schematic of the mevalonate pathway in which inhibition of the enzyme HMG 
CoA Reductase by statins inhibits the production of mevalonate and its downstream 
compounds. Studies of statin-induced myopathy independent of exercise suggest the 
following: (A) pathway inhibition at squalene synthase is not associated with myopathy; (B) 
ubiquinone’s role is less clear, but there is evidence indicating reductions do not induce 
myopathy; and (C) terpenoid depletion and subsequent reductions in prenylated proteins are 
associated with greater myopathy. No studies to date have investigated the potential 
contribution of these pathways in the exacerbation of statin-associated myopathy with 
exercise. 
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Finally, it has been suggested that statin-associated myopathy may be related to 
mitochondrial dysfunction 
59,60
. An elevated lactate/pyruvate ratio 
59
, intramuscular lipid-droplet 
accumulation 
60
, and impaired ß-oxidation 
61
 have all been found in statin-treated muscle. 
Furthermore, transmission electron microscopy of statin-treated muscle fibers has shown that 
mitochondrial damage is present even in fibers which appear otherwise unaffected 
43
. Because 
exercise dramatically increases oxygen consumption and consequently the activity of a muscle’s 
metabolic pathways—of which mitochondria are an essential component—this presents an obvious 
route through which exercise may exacerbate statin-associated myopathy (Figure 1.2).  However, 
this possibility has been examined only indirectly in the current research, with conflicting results 
44,43
.  
 
POTENTIAL ROLE FOR EXERCISE: DIRECTED RESEARCH 
Unfortunately, while the literature addressing the mechanisms behind statin-associated 
myopathy is limited, literature specifically addressing the interactions of statin treatment and 
exercise is even more so. While contributory, a large proportion of this literature is based on blood 
markers of muscle damage, and currently less than half a dozen articles are available in the 
literature that could be considered controlled, mechanistic investigations of the effects of statin use 
on exercise associated muscle damage. Also, before addressing this literature it is important to note 
the distinction between an exacerbation of statin-associated myopathy by exercise and an 
exacerbation of exercise-induced damage by statins. Literature using blood creatine kinase (CK) 
generally addresses only the latter, and does not determine a change in myopathy risk with 
exercise. In fact, this is true of the vast majority of literature addressing statins and exercise, which 
examine the response to a single exercise bout. However, the line between exacerbated statin-
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associated myopathy by exercise and exacerbated exercise-induced damage by statins is currently 
unclear, as no literature currently exists to determine whether elevated myopathy risk with exercise 
is the result of cumulative elevations in the damage response to single exercise bouts, or if distinct 
pathways for statin-induced damage are activated by exercise, or both. 
 
CREATINE KINASE 
In the early 1990’s numerous studies were conducted addressing the combination of 
exercise and statin treatment. Until that time, both exercise and statin therapy had been shown to 
independently increase CK levels, but the interactions between the two had not been examined. 
Two studies investigating the interaction of simvastatin 
62
 or lovastatin 
63
 treatment and exercise 
found that statins exacerbated the CK response to a single bout of cycling and downhill walking, 
respectively. Alternatively, two studies, Reust et. al. 
64
 and Thompson et. al. 
65
 examined the effect 
of 4 weeks of Lovastatin treatment (40mg/day and 20mg/day, respectively) on the serum CK 
response to a single bout of eccentric or concentric treadmill exercise, respectively, and neither 
research group found evidence that Lovastatin treatment significantly elevated the CK response to 
exercise. However, while methodologically sound, the studies reporting no interaction between 
statins and exercise on the CK response both had small sample sizes, with 10 and 14 subjects for 
Reust et. al. and Thompson et. al., respectively. 
Thompson et. al. 
66
 later completed a similar investigation including a greater number of 
subjects who performed both resistance exercise and treadmill exercise. Forty-nine subjects with 
LDL-C levels above 130mg/dL (aged 18-85 years) were randomly assigned to five weeks of 
Lovastatin (40mg/day) or placebo treatments. After 4 weeks of treatment, subjects performed a 
downhill walking exercise consisting of three 15-minute intervals on a 15% decline. One week 
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later, the subjects performed a bicep curl exercise, consisting of 4 sets of 10 repetitions at 50% of 
their 1-repetition maximum. Serum CK measures were taken immediately prior to each exercise 
intervention, and subsequent measures were taken every 24 hours extending to 96 hours post-
treadmill and 120 hours post-bicep curl 
66
. Following the bicep curl exercise there were no 
significant differences in CK levels between Lovastatin and placebo groups. In contrast, after the 
downhill treadmill exercise the Lovastatin-treated group had higher CK levels than the placebo 
group at all time points, reaching statistical significance at 24 and 48 hours post-exercise.  These 
finding suggest that the mode of exercise, type of muscle action, and muscle group may all 
contribute to the interaction of statin-induced damage and exercise.  Specifically, downhill walking 
has a large eccentric component and involves large muscle groups (i.e. quadriceps) and eccentric 
or lengthening exercise is a well-established model to induce muscle damage as compared to 
concentric or isometric exercise 
67,68
.   
While eccentric exercise in combination with statin treatment may be associated with 
greater muscle damage as assessed by CK levels, increased statin dosage may not exacerbate the 
damage.  Kearns et al. investigated the relationship between atorvastatin dosage and the serum CK 
and muscle soreness response to a single downhill treadmill exercise bout 
69
. Their results 
suggested that the degree of elevation in CK levels and soreness after a damaging exercise bout 
may not be related to the prescribed statin dosage.  Specifically, groups treated with 10mg/day or 
80mg/day both showed similar responses. Additionally, the damage outcome measures—serum 
CK and muscle soreness—were not significantly correlated within subjects at either dose. 
Unfortunately, no placebo group was included in this study, leaving the results open to multiple 
interpretations. If maximal damage occurred at a dose of 10mg/day, this could explain the absence 
of an exacerbated damage responses at 80mg/day. Alternatively—since no placebo was included—
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it is possible that neither group experienced any further damage due to statin treatment, i.e., had a 
placebo group been included similar CK and soreness responses may have been observed with 
placebo and 10 or 80 mg/day of atorvastatin.  Consequently, the relationship between statin dose 
and exercise-exacerbated myopathy remains unresolved. Further, in non-exercising statin users the 
relationship between myopathy and statin dose is also conflicting, reporting that myopathy may 
11,7
 
or may not 
70,71
 be dose-responsive. 
The lack of correlation between muscle soreness ratings and CK levels in the study by 
Kearns et al. highlights a considerable issue with this body of research. The serum CK response to 
exercise is unreliable and does not necessarily correlate with more robust measures of muscle 
damage 
72-74
. Furthermore, a large number of studies have reported manifestations of statin-
induced myopathy without corresponding elevations in serum CK levels 
75,76,60,77,7
.  Taken 
together, this contributes an additional element of uncertainty to the literature, as the utilization of 
serum CK as a marker of muscle damage may underestimate the prevalence and/or severity of 
statin-associated myopathy, especially in combination with exercise. Consequently, studies 
mechanistically examining this interaction through more reliable and descriptive measures are 
needed. 
 
 
POTENTIAL MECHANISMS CONTRIBUTING TO STATIN-INDUCED MYOPATHY WITH EXERCISE 
As discussed, there is a reasonable body of research reporting potential cellular 
mechanisms underlying statin-induced myopathy independent of exercise, and the serum CK 
response to a single exercise bout after a period of statin therapy has been examined using several 
modes of exercise. However, research investigating the cellular mechanisms behind the apparently 
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antagonistic interactions between physical activity and statin treatment is extremely limited, as 
evidenced by only two studies to date which have examined this important subset of statin-
associated myopathies.  
A study by Urso et. al. quantified skeletal muscle gene expression eight hours after an 
eccentric exercise bout in human subjects receiving four weeks of Atorvastatin (80mg/day) or 
placebo. They found significant statin-induced alterations in genes involved in the ubiquitin 
proteasome pathway (UPP), protein catabolism, inflammation, and apoptosis 
78
. Unfortunately, this 
study did not measure protein levels, and thus it is unknown whether these mRNA changes were 
observed at the functional protein level. However, animal models investigating catabolic stimuli 
such as muscle damage, disuse, or denervation have shown that up-regulation of UPP genes is 
associated with increases in protein catabolism 
79-82
. Interestingly, while previous research suggests 
that statin-induced myopathies may be partially due to apoptosis 
35-38
, this study reported that 
genes involved in catabolism and the UPP were up-regulated, while genes involved in apoptosis 
and inflammation were down-regulated after exercise in statin-treated compared to placebo-treated 
subjects. Among the genes with altered expression, the authors identified the UPP gene FBXO3—
which showed a four-fold increase in expression—as the strongest candidate contributing to the 
exacerbation of exercise-induced myopathy with statin treatment 
78
. While the exact role for 
FBOXO3 is unknown, as an F-box-motif protein, FBOXO3 likely selects specific proteins for 
ubiquitin tagging and subsequent degradation in the proteasome. However, which particular 
protein or proteins FBOXO3 has an affinity for is not presently known. If FBOXO3 targets 
important structural or contractile proteins its upregulation could clearly contribute to statin-
associated muscle damage. Thus, further investigation is needed into the potential physiological 
actions of FBXO3 and other UPP proteins during exercise-induced myopathy in statin users. 
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 A review of the literature finds only a single study investigating the effects of exercise on 
statin-induced muscle damage beyond performance of a single exercise bout 
43
. This is clearly 
important, as a consistent exercise training program—not a single exercise bout—is necessary to 
observe positive changes in lipid profiles. Seachrist et. al. examined both serum and muscle 
measures after two weeks of concomitant treadmill running and statin treatment in rats receiving 
various cerivastatin doses.  While exercise alone or cerivastatin alone at doses of 0.5 and 1mg/kg 
significantly elevated serum CK levels, these levels were not further elevated by the combination 
of Cerivastatin and exercise. Serum levels of the muscle and liver enzymes aspartate 
aminotransferase (AST) and alanine aminotransferase (ALT) were increased and blood glucose 
was decreased by high-dose cerivastatin treatment; however, none of these measures were affected 
by the combination of cerivastatin and exercise. Further, intramuscular cerivastatin concentrations 
were reflective of plasma concentrations following repeated administration, indicating that 
cerivastatin may not accumulate in muscle. Muscle concentrations of cerivastatin were not affected 
by the addition of exercise, suggesting that muscle contraction per se does not lead to a potentially 
damaging accumulation of the drug in the muscle. However, it should be noted that while there has 
been no indication of the various statins causing myopathy through different pathways, they are 
well known to have different lipophilic and hydrophilic properties. Differences in these properties 
affect membrane permeability, and therefore these findings on cerivastatin’s muscle 
pharmokinetics may not necessarily translate to other statins.  
 In contrast to the aforementioned blood measures, an interaction effect of cerivastatin and 
exercise was found in numerous muscle measures. Quadriceps muscle weight was reduced in 
exercising mice receiving statin treatment at 1mg/kg compared to exercising mice receiving 
placebo. Histological examination of muscle from sedentary rats treated at 1mg/kg showed 
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fragmented sarcoplasm and vacuoles, centrally-located nuclei, and an absence of cross-striations. 
Importantly, the addition of exercise resulted in increased severity of these damage markers. 
Statin-induced damage was seen in all muscles studied with the exception of the soleus, and the 
damage was exacerbated by exercise in the gastrocnemius, quadriceps, psoas, and extensor 
digitorum longus (EDL). In addition to the aforementioned damage markers, muscles that were 
subjected to both exercise and statin treatment had increased infiltration of inflammatory cells and 
mineralization in degenerated areas.  
 Using Transmission Electron Microscopy, statin (0.5 mg/kg)-associated damage was 
detected in subsarcolemmal mitochondria in psoas and EDL fibers that appeared otherwise 
unaffected, but this was not exacerbated by exercise. At 1mg/kg however, exercise increased the 
degeneration of mitochondria and other subsarcolemmal organelles, as well as caused 
inflammatory cell infiltration and glycogen accumulation. Structural changes included 
disorganized myofiber structure, missing z-bands, and fragmented myofibrils. These changes were 
not seen in muscles that were only statin-treated. 
Consistent with the literature 
44,83,84
, degeneration induced by statin treatment was specific 
to muscles composed of predominantly type II myosin heavy chain (MHC), leaving muscles 
composed of predominately type I MHC—such as the soleus—unaffected. Additionally, it was 
shown that the increased propensity for damage to type II MHC fibers does not appear to be the 
result of different statin pharmacokinetics between MHC fiber types, as both type I and type II 
fibers had similar intramuscular cerivastatin concentrations 
43
. 
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FIGURE 1.2: POTENTIAL PATHWAYS OF STATIN & EXERCISE INTERACTIONS 
 
Figure 1.2: Potential pathways for the exacerbation of statin-associated myopathy with exercise. 
Increased Ubiquitin Proteasome Pathway (UPP) activity and elevated mitochondrial damage 
have both been shown to occur with the addition of exercise in statin users. The remainder 
of the illustrated pathways currently remain speculative, however exercise increases energy 
flux, which would likely impact damaged mitochondria. Exercise also activates the MAPK 
pathway and can lead to glycogen depletion. 
 
INDEPENDENT ROLE FOR HYPERCHOLESTEROLEMIA 
 In 1995 the myoglobin (Mb) and CK response to exercise in two equicholesterolemic 
groups of male patients with heterozygous familial hypercholesterolemia—with one group 
receiving simvastatin and the other a lipid-lowering diet—was investigated 85. To assess the 
independent role of cholesterol, results were also compared to a normocholesterolemic control 
group. All groups were matched for age, body mass index (BMI), and physical activity, and the 
two hypercholesterolemic groups were matched for LDL cholesterol. There were no differences in 
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serum Mb or CK responses to exercise between hypercholesterolemic groups, but both showed 
elevated responses compared to healthy controls. These results suggest that myopathy attributed to 
statin therapy in combination with exercise may be due in part to high cholesterol levels, and not 
statin treatment per se.  In contrast, other controlled trials in subjects without heterozygous familial 
hypercholesterolemia that were normocholesterolemic at the time of exercise 
43,66,78
 found that 
statins did play an independent role in the exacerbation of myopathy with exercise.  These studies 
suggest that hypercholesterolemia is clearly not the only factor in greater statin-induced myopathy 
with exercise .  
Individuals with a wide range of cholesterol values have been used to examine potential 
interactions between statin treatment and exercise in contributing to myopathy. Interestingly, 
positive interactions between statins and exercise have generally been found at low cholesterol 
values—i.e. healthy rats 43, and humans w/LDL below 110mg/dL 66,78—while subjects with higher 
LDL values (>190mg/dL) tended to show no adverse interactions 
64,85
. Downhill walking has been 
used in studies finding both positive 
66
 and negative interactions 
85
.  Therefore, directed research is 
needed to determine whether this is an artifact of the literature or whether cholesterol below a 
certain level could potentially predispose individuals to an elevated level of myopathy with the 
combination of exercise and statins that is either masked or not present in individuals with higher 
cholesterol levels. It would also be of interest to examine whether the time-course of cholesterol 
reductions with statin therapy is temporally related to changes in the incidence of myopathy. 
 
MUSCLE GLYCOGEN AND FIBER TYPE 
It has been reported that glycogen-depleted muscle fibers are more susceptible to statin-
induced damage than glycogen-rich fibers 
86
. Since certain types of exercise result in significant 
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glycogen depletion in the exercising muscle 
87
, this suggest another potential mechanism 
underlying the elevated risk for statin-associated myopathy with exercise. Interestingly, diabetes 
has been associated with reduced baseline glycogen synthesis 
88,89
 and diabetic individuals are 
more susceptible to statin-associated myopathy 
90,23
,  Additionally, insulin resistance may impede 
the ability to restore muscle glycogen after glycogen-depleting resistance exercise 
91
. These data 
present an interesting potential contribution of exercise-induced muscle glycogen depletion to the 
exacerbation of myopathy associated with exercise and statin use.  
 Alternatively, several studies have shown that muscles composed of predominately type II 
MHC fibers are more susceptible to statin-induced damage than predominately Type I MHC 
muscles 
44,43,83,84
. However, depletion of muscle glycogen is greater in Type I fibers at exercise 
intensities below VO2max, and depletion may not be higher in Type II fibers until very high 
exertion levels 
87
. Paradoxically, available literature examining statins and exercise has used 
submaximal exercise intensities, which would not be expected to deplete glycogen in the more 
myopathy-prone Type II fibers. Research examining both a resistance and an aerobic bout of 
exercise while receiving statin treatment found that the aerobic exercise (downhill walking for 
45min at 65% maximum heart rate)—which could reasonably be expected to reduce glycogen 
levels in type I fibers—was associated with an elevated CK response to exercise when receiving 
statin treatment.  In contrast, low-intensity (50% 1-repitition maximum) resistance exercise—
which would not be expected to appreciably reduce glycogen levels in either fiber type—showed 
no effect on CK levels with the combination of exercise and statin treatment 
66
. Additionally, some 
research has implicated mitochondrial dysfunction and impaired -oxidation in myopathy 
43,61,60
, 
which—if present—may further complicate this issue by altering glucose/glycogen kinetics from 
that expected in healthy muscle and making glycogen depletion even more likely.   
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Taken together, these findings present an intriguing and perplexing set of data. As such, 
directed research should be aimed at resolving the potential role of glucose/glycogen kinetics 
during and after exercise in statin-associated myopathy and its interaction with exercise.  Further, 
based upon the differences in glycogen storage and utilization among fibers with different MHC 
fiber types, future studies should address potential interactions between glycogen kinetics and 
muscle MHC fiber type profile.    
 
EXERCISE TRAINING VS. A SINGLE EXERCISE BOUT 
Currently, little information is available addressing how exercise frequency, intensity, or 
modality may affect the risk of statin-related myopathy. While not the rule, the majority of current 
exercise and statin investigations commonly utilize a single exercise bout and indirect measures 
(i.e. serum CK) of muscle damage 
64,62,65,66,78,63
.  While several human studies 
63,62,66
 have shown 
that statin treatment increases muscle damage in response to a single exercise bout, only a single 
animal study has directly examined multiple exercise bouts in conjunction with statin treatment.  
However, all exercise groups in this study followed identical protocols for incomplete 
accustomization to the exercise before the initiation of statin treatment 
43
. Therefore, no 
comparisons between unaccustomed or fully-accustomed animals were possible. 
To our knowledge, no study has yet addressed chronic exercise training prior to statin 
treatment. In the current literature there is generally accustomization to the statin treatment prior to 
exercise, but never accustomization to exercise before beginning statin treatment. As such, it is not 
possible to account for the well-established differences in the muscular response to an 
unaccustomed exercise bout as compared to the response to an acute exercise test after a period of 
training. In response to a novel exercise stimulus, rapid adaptive responses occur within the muscle 
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such that as little as one bout of novel exercise can be sufficient to protect against damage during 
subsequent bouts 
92-94
. Additionally, exercise training induces further well-established metabolic 
and structural adaptations within the muscle beyond those stimulated by a single novel stimulus. 
For instance, endurance training is associated with significant increases in the expression of 
numerous enzymes related to respiratory capacity 
95
, and improvements in subsarcolemmal 
mitochondria with training may increase the ability to maintain cell membrane integrity 
96
. 
Resistance training, on the other hand, can increase overall strength, improve peak rates of force 
development, and increase the ability to recruit high-threshold motor units 
96
. Because of these and 
other considerable adaptations made to both an initial, novel exercise bout and to subsequent 
exercise training the responses evoked by a single exercise stimulus while on statin therapy such as 
predominate the literature may not translate to muscles after chronic training. 
Furthermore, there are numerous potential mechanisms whereby exercise training might be 
successful in attenuating statin-induced muscle damage. Possible mechanisms for this include the 
up-regulation of protective heat-shock proteins (Hsp), suppression of apoptotic factors such as 
caspase-3, and increases in muscle ubiquinone content.  
A primary focus of our laboratory has been the potential protective role of Hsps during 
muscle adaptation.  The protective effects of Hsp70, Hsp25 and B-crystallin have been 
documented in many cell types, but growing evidence supports their important role in maintaining 
skeletal muscle structure and function 
97
. In muscle, the Hsps have been shown to reduce oxidative 
stress 
98
, inhibit apoptosis 
99
 and potentially attenuate muscle damage 
100-104
. Interestingly, Hsp70, 
Hsp25 and B-crystallin are more highly expressed in fibers composed of predominately type I 
MHC 
105-109
, which is the type of muscle fiber that appears to be least susceptible to statin-induced 
myopathy. Currently, data on statin treatment and Hsp expression is conflicting, showing either 
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increases 
110,111
 or decreases 
112-114
 in expression depending on the tissue examined. It is likely 
that—similar to statin’s apoptotic actions—their effects on Hsp expression are cell-type dependent, 
and future studies are necessary to investigate the effects of statin therapy on Hsp expression in 
skeletal muscle.  
In addition to stabilizing muscle structure and potentially reducing the risk for muscle 
damage, the Hsps can inhibit both the intrinsic and extrinsic apoptotic cell death pathway at unique 
as well as common points 
115-117
. Additionally, Hsp25 protein levels are positively associated with 
reductions in activated caspase-3 activity in vivo 
118-120
. Since statin-induced apoptosis is 
associated with increases in caspase-3 and -9 expression levels in vitro, if muscle apoptosis is 
induced in vivo any intervention to block these pathways could reduce the incidence of statin-
associated myopathy. Importantly, chronic increases in muscle activation and loading (i.e. training) 
are associated with increased muscle Hsp content 
121-123
, and could therefore potentially attenuate 
statin-associated muscle damage. 
Finally, several studies have shown that exercise training increases ubiquinone levels in 
skeletal muscle 
124-126
. While the role for ubiquinone levels in statin-induced myopathy is not clear, 
if reductions in ubiquinone are a factor in myopathy, this presents yet another pathway through 
which exercise training could benefit individuals seeking to improve lipid profiles through both 
exercise and statin treatment.  However, there is some indication that increases in ubiquinone 
levels with exercise occur only in the already myopathy-resistant type I fibers 
125
. 
While no human studies have directly investigated the effects of an exercise training 
intervention on statin-induced myopathy, a cross sectional study of athletes has been reported. 
Sinzinger and O’Grady 15 examined how professional athletes with familial hypercholesterolemia 
would tolerate statin therapy. They reported that of 22 athletes, only 6 were able to tolerate statin 
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treatment, and only 3 of these 6 tolerated the first statin prescribed (athletes were tried on 
atorvastatin, fluvastatin, lovastatin, pravastatin, and simvastatin before determining intolerance). 
These athletes participated in fourteen different athletic disciplines and showed no indication of 
varying tolerance based on modality. However, these data must be interpreted carefully, as the 
recent intensity, duration, or frequency of these athletes’ training regimens was not reported, and 
thus their training state at the initiation of statin therapy—and beyond—is not known. 
Additionally, the interpretation of ―tolerate‖ was not defined, as the presenting symptoms were 
neither quantitatively nor qualitatively defined. Finally, and perhaps most importantly, no placebo 
treatment was included in the drug rotation. Therefore, while data indicating statin intolerance in 
professional athletes would argue against exercise training being protective, it cannot in fact be 
determined from the published data whether these athletes experience the same or lower levels of 
myopathy as less active individuals but are more sensitive to changes or perceived changes in 
performance level or pain, or whether high levels of athletic training may make an individual more 
susceptible to muscular complications.  
 
CONCLUSIONS AND FUTURE DIRECTIONS 
Statins are currently the most effective and common cholesterol-lowering drug, and are 
overall quite safe. The most common complication is some degree of skeletal muscle myopathy, 
generally seen in only a small percentage of patients. However, this complication is exacerbated by 
physical activity, and therefore presents an unfortunate obstacle to the minimization of 
cardiovascular disease risk and to optimal physical activity levels that has not been adequately 
addressed in the literature. 
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 Pathways underlying statin-associated myopathy are not well understood, though several 
potential mechanisms have been identified, including the induction of apoptosis, mitochondrial 
dysfunction, and—especially as it pertains to the prenylation of small GTPase signaling 
molecules—terpenoid depletion. How these potential mechanisms may interact negatively with 
physical activity is even more uncertain. However, mechanistic research has shown that the 
combination of exercise and statins may exacerbate mitochondrial damage and degrade muscle 
proteins via up-regulation of ubiquitin proteasome pathway activity.  
 We have highlighted several areas which may warrant future investigation; A) we propose 
that glucose/glycogen kinetics during exercise may play a key role in the interaction between 
statins and exercise.  Glucose/glycogen utilization and re-synthesis are significantly impacted by a 
single bout of exercise and—importantly—glycogen utilization changes with chronic exercise 
training (i.e. training is associated with greater lipid utilization at a given absolute intensity). For 
example, future studies could utilize dietary interventions and pre/during/post-exercise glucose 
supplementation to manipulate muscle glycogen levels and quantify statin-associated muscle 
damage under acute exercise and exercise-trained conditions. This type of information would help 
clinicians/dieticians provide dietary recommendations that could potentially reduce the occurrence 
of statin-associated muscle damage with exercise.  B) The role of hypercholesterolemia per se has 
not been well examined, either in relation to general statin-associated myopathy or with the 
interaction of exercise, though the literature suggests it may play an independent role. It would be 
of interest to complete an intervention study to determine if changes in statin associated muscle 
damage are correlated to changes in lipid profiles. Further, an exercise training intervention would 
suggest if any corresponding changes in damage and cholesterol are due to training induced 
changes in muscle, improved lipid profiles, or a combination of both factors. C) All physical 
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activity cannot be treated equally in the examination of statin-associated myopathy. Research 
differentiating between an exercise bout and exercise training—as well as between different 
modalities, namely resistance and aerobic, and shortening vs. lengthening muscle actions—is 
needed. Specifically, there is a clear need for controlled intervention studies to investigate if prior 
exercise training alters myopathy risk or statin-associated elevations in exercise-induced damage, 
and whether these interactions are dependant on exercise modalities.  If future research finds that 
exercise frequency or modality affects statin-associated myopathy it would present data of 
immediate importance and use to clinicians.  D) Serum CK is most commonly used to evaluate the 
exacerbation of myopathy with exercise and statin use; however, it is indirect and is not a 
consistently reliable marker of exercise-induced damage or statin-associated myopathy. Research 
utilizing more direct muscle assessments is needed, as the utilization of serum CK has likely 
contributed to an under-appreciation of the prevalence of statin-associated myopathy with exercise. 
Animal models lend themselves well to both functional and direct damage assessments, and 
functional muscle testing and limited biopsy research is practical in human subjects. Further, while 
it may not contribute mechanistic data, muscle strength presents perhaps the most reliable measure 
of muscle function, and further, provides insight into whether statin-associated muscle damage 
actually results in physiological performance decrements. We would suggest that in the process of 
examining exercise/statin interactions, future research efforts should also work towards building a 
reliable literature base of both functional muscle outcomes and direct assessments of muscle 
damage. 
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CHAPTER 2: EXPERIMENTAL METHODS 
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OVERVIEW.  
These experiments used C57BL/6J male mice (Jackson Labs) for all procedures. All 
methods involving live animals were approved by the Illinois Institutional Animal Care and Use 
Committee. 
The experimental design encompassed three treatment conditions: activity during days 1-14 
(either running wheel access or no wheel access), activity during days 15-28, and saline or statin 
treatment during days 15-28. With the exclusion of groups having access to the running wheel for 
the first two weeks but not the second, this creates six groups, as shown below. Each group 
required 10 mice (see power analysis, statistical methods section), for a total of 60 mice. All mice 
were 10 weeks old at the initiation of statin or saline injections. The two week time-points were 
chosen in light of preliminary data from our own laboratory showing significant alterations in Hsp 
and Caspase-3 expression by running wheel exercise at two weeks, as well as data from other 
researchers indicating that the current statin treatment induces myopathy within two weeks 
123,44,43
. 
 Treatment groups were organized as shown in table 2.1. To reduce the total number of 
animals necessary, groups Sed/Saline and Sed/Statin were used as the control groups for Aims 1, 
2, & 3. 
Table 2.1 
Group ID Days 1-14 Treatment Days 15-28 Treatment 
Sed/Saline Sedentary Sedentary,  Saline inj. 
Sed/Statin Sedentary Sedentary,  Statin inj. 
Novel/Saline Sedentary Running Wheel,  Saline inj. 
Novel/Statin Sedentary Running Wheel,  Statin inj. 
Accust/Saline Running Wheel Running Wheel,  Saline inj. 
Accust/Statin Running Wheel Running Wheel,  Statin inj. 
Table 2.1: Treatment groups formed by the combinations of days 1-14 activity, days 15-28 activity, 
and days 15-28 injections.  
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All mice were housed individually, fed food (standard chow diet) and water ad libitum, and 
kept on a 12/12 light/dark cycle. The running wheel mice had constant access to an 11.5 cm 
running wheel (Mini-Mitter) in their cage. These running wheels were equipped with magnetic 
reed switches and a small bicycle computer (Sigma), which allowed daily tracking of distance 
covered and time spent in the wheels. Running wheel activity was recorded every twenty-four 
hours during the light cycle.  
Starting on day 15, mice in the novel exercise groups were moved into running wheel 
cages, and all mice began to receive daily injections of either saline or cerivastatin. Cerivastatin 
(Sequoia Research Products) injections were given intraperitoneally at a dosage of 1mg/kg, 
delivered as a suspension at 0.25mg/ml in sterile saline. Previous reports have confirmed this 
dosage and duration to consistently cause myopathy, but not to the extent that the animals will not 
exercise 
123,44,43
. As the mice perform the majority of their running wheel activity during the dark 
cycle, injections were given towards the beginning of the light cycle in order to minimize any 
direct effects of the injections themselves on activity. Running wheel activity continued to be 
monitored daily up until day 28. 
 
DATA AND TISSUE COLLECTION: 
Force Measurement:  
Setup: On day 28, all mice had measurements taken for the maximum isometric 
contraction strength of the hindlimb plantar flexors. The force-measurement apparatus consists of a 
servomotor and analog control unit (model 305C-LR, Aurora Scientific), a square-wave stimulator 
(model 2100, A-M Systems), and a PC running a customized LabView 8.2 program to control both 
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the servomotor and the stimulator. The servomotor system was calibrated by placing a series of 
known weights at a distance of 20mm from the axis and creating a torque/voltage standard curve.  
For force measurement, mice were first weighed, then fully anesthetized by the 
administration of 90-120mg/kg Ketamine, 9-12mg/kg Xylazine IP. Surgical-plane anesthesia was 
confirmed by pinching the pad of the hind foot. Once the anesthesia took full affect, the mice were 
placed on a table warmed to 37°C, where all further surgical procedures were performed.  
Surgery: An incision was first made on the lateral thigh of the mouse, parallel and 
superficial to the femur. At this point the illiotibial band is visible, and the hamstring and 
quadriceps muscle groups were dissected apart, allowing access to the sciatic nerve, located 
between the hamstrings and femur. Further dissection into the popliteal fascia allowed the split of 
the sciatic into the tibial and common peroneal nerves to be visible. The common peroneal branch 
was identified visually and confirmed by a dorsiflexion muscle twitch upon gentle pinching with a 
forceps. At this point the common peroneal nerve was severed, ablating innervation to the anterior 
compartment of the lower limb and ensuring stimulation of only plantarflexor muscles upon 
stimulation of the sciatic. 
The ankle of the mouse was then fixed in the servomotor’s footplate, with the talus (the 
rotational center of the ankle joint) aligned with the servomotor axis. The mouse was then 
positioned so as to place the knee joint at 90° and the ankle at 90°, where the knee was 
immobilized with an alligator-clip style clamp about the femoral condyle. 
Two hooked-needle electrodes were then placed proximal to the knee on the sciatic nerve, 
with the two electrodes approximately 1mm apart and contacting only the sciatic and not adjacent 
muscle tissue. The sciatic nerve was then stimulated at 250hz for 1.5 seconds to evoke a maximal 
contraction, during which time the servomotor held the ankle to 90° in order to measure isometric 
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force production. This stimulation was repeated 9 times with a recovery period of 5 seconds 
between contractions (6.5 seconds from contraction 1’s start to contraction 2’s start), for a total of 
10 measurements. The highest of the 10 acquired data points was taken as the maximum. The final 
contraction was compared to the maximal contraction and expressed as a percentage of maximal 
force to provide a measure of fatigability. Data were recorded by a customized LabView program 
(National Instruments) to provide a plot of ankle-torque/time. 
 
Tissue Collection: 
The mice were euthanized immediately after the completion of the force-measurement 
protocol. At this time, blood was drawn from the inferior vena cava into EDTA treated syringes 
and deposited in EDTA treated microcentrifuge tubes on ice. Subsequently, the gastrocnemi were 
isolated from the hindlimbs and immediately snap-frozen in isopentane chilled by liquid nitrogen, 
then stored at -80°C for subsequent analysis. For each mouse, muscles from the left limbs were 
used for analysis, as this is the limb that was not subjected to the force-measurement protocol. 
After tissue collections whole blood was centrifuged at 1200g for 10 minutes at 4°C. Plasma was 
then extracted and frozen at -80°C until analysis. 
 
Protein Isolation: 
Pre-weighed muscle samples (~40 mg) were homogenized in 10 volumes of an ice-cold 
buffer containing 50mM Tris _HCl (pH 7.8), 2 mM potassium phosphate, 2 mM EDTA, 10% 
glycerol, 1% Triton X-100, 1 mM dithiothreitol, 3 mM benzamidine, 1 mM sodium orthovanadate, 
10 mM leupeptin, 5 mg/ml aprotinin, and 1 mM 4-[(2-aminoethyl) benzenesulfonyl fluoride], and 
supplemented with protease and phosphatase inhibitors (Sigma) using a motor driven glass pestle 
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in a textured glass test tube. Homogenates were immediately centrifuged at 12,000g for 12 min at 
4°C and the supernatant removed as the detergent-soluble fraction. Protein concentrations were 
then determined by Bradford assay (Biorad) using bovine serum albumin for the standard curve, 
after which samples were saved immediately in aliquots at –20°C for subsequent use in Western 
blotting. 
 
Western Blot Analysis: 
The necessary volume for loading 30μg of total protein was determined from protein assay 
data, and the sample was boiled in loading buffer for 5 minutes at 95°C. Proteins were separated 
by sodium dodecylsulfate–polyacrylamide gel electrophoresis (SDS-PAGE) (12.5% acrylamide) 
and transferred to PVDF membranes (Millipore). After transfer, successful equal loading, 
electrophoresis, and transfer were confirmed by reversible Ponceau-S staining. Only membranes 
showing equal loading across all samples were used for subsequent antibody staining and analysis. 
Ponceau-S staining was removed by water rinse and a 5 minute wash in TBS/0.15% Tween, after 
which the membranes were blocked for a minimum of one hour in Tris-buffered saline (TBS) 
containing 5% powdered dry milk. Following blocking, the membranes were incubated overnight 
at 4°C in primary antibodies (Hsp25 & αB-Crystallin, StressGen, 1:5000. Caspase-3, 
Upstate/Millipore, 1:1000. Caspase-9, Cell Signaling Technologies, 1:1000) in TBS w/2.5% 
bovine serum albumin (BSA).  After primary antibody incubation, membranes were washed three 
times with TBS/0.15% Tween, then incubated in anti-rabbit IgG secondary antibody (Amersham 
Biosciences) at 1:5000 for one hour at room temperature. Following the secondary antibody, the 
membranes were again washed three times in TBS/0.15% Tween. Membranes were then 
developed using enhanced chemiluminescence (Amersham Biosciences) detected by a computer-
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controlled charge-coupled device (CCD) camera (Fujitsu). Developed images were analyzed using 
ImageQuant software (GE Healthcare).  
 
Plasma Creatine Kinase:  
Plasma aliquots were thawed to 4°C, then analyzed by a CK activity assay (BioAssay 
Systems) as per the manufacturer’s instructions. Briefly, this assay provides the substrates 
necessary to allow CK to convert creatine phosphate and ADP into creatine and ATP, and for the 
created ATP to ultimately be used to oxidize NADP to NADPH. The created NADPH can then be 
quantified by spectrophotometry. 
 
STATISTICAL METHODS: 
Power Analysis/Justification of Sample Size:  
All power analysis calculations were done using the Power and Precision (Biostat) 
statistical software. Parameters for the power analysis were an alpha level of .05 and power of .80. 
Anticipated effect sizes for each effect are described below. 
At this time, data on muscle force production capabilities with the combination of statin 
treatment and exercise does not exist in the literature. Additionally, available histology data 
addressing these treatments has been collected on subjective and discontinuous scales that do not 
lend well to power analysis. Therefore, we took available data from our own laboratory regarding 
force production measurements to perform this analysis, and calculated the necessary number of 
mice per group to detect what would be a clinically relevant outcome. The primary outcome of 
interest was the interaction effect between exercise and statin treatment in a 2x3 
Regression/ANOVA model. However, this effect was found to be severely underpowered at any 
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reasonable group size. Therefore, analysis was performed on the primary group differences of 
interest: between the Sed/Statin and Sed/Saline groups, and the Novel/Statin and Accust/Statin 
groups. Previous data from our laboratory indicates that the group mean for the Sed/Saline group 
should be ~40 grams of force, and that the standard deviation within groups is ~4.0 grams. A 15% 
decrement in force-production capability was deemed a clinically relevant outcome, which equates 
to a 6 gram decrement. With Sed/Saline and Sed/Statin group means at 40±4 and 34±4 grams, 
respectively, the predicted power for 8 mice per group was 0.78. Since group differences in the 
two exercise-treated groups were hypothesized to be greater than the differences found in the 
sedentary mice, this group size was deemed appropriate for all groups. To account for unexpected 
mortality, non-voluntary exercisers, and potential statin nonresponders, a final group size of 10 
mice was decided. 
 
Data Analysis:  
All analyses were performed using SPSS version 15 statistical software, setting alpha to 
reject the null hypothesis at 0.05. There were two treatment conditions (statin/saline), and as there 
were no groups exercising for the first two weeks but not the second two, the activity conditions 
(sedentary, novel, accustomed) were analyzed as 3 distinct treatments, rather than two distinct day 
1-14 treatments and two distinct days 15-28 treatments. Therefore, each outcome measure—with 
the exception of running wheel activity (see below)—was submitted to a separate 2x3 multiple 
regression model including a term for the injection*exercise interaction. First order autocorrelation 
was examined by Durbin-Watson’s D and normality by Shapiro-Wilk. Equality of variance was 
tested by Spearman’s Correlation Coefficient for correlations between model-predicted values and 
the absolute values of the residuals. Transformations were performed if necessary to satisfy these 
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model-assumption tests. Post-hoc analyses were performed only if significant main or interaction 
effects were found. In the case of significant main effects, group differences were only examined 
across the treatment for which the main effect existed. If within-group variances were equal across 
groups, post-hoc analysis was performed by Tukey post-hoc test. If homogeneity of variance did 
not exist, post-hoc analysis was run by repeated t-tests. Running wheel distances were examined as 
a possible regression covariate for both the force measurements and the CK measures. 
  
Outcome Correlations:  
Pearson correlation tests were performed to examine relationships between muscle force-
production ability, plasma CK levels, and running wheel activity. Significant correlations were 
accepted at p<0.05. 
 
Running Wheel Data:  
Running wheel data was analyzed as a set of time-points of interest by independent-
samples t-tests. 3-day activity averages were calculated for each individual mouse for days 12-14, 
15-17, and 26-28. Comparisons were only made within time-points between saline and statin 
treatments, and not between novel and accustomed exercise groups. 
 
Western Blotting Analyses:  
In order to allow the most accurate possible analyses, each gel was run with one animal 
from each group. The cumulative absorbance from each of the 6 samples per gel for the protein of 
interest in the gel was then measured, and each sample’s relative contribution to the total gel 
absorbance was calculated and expressed as a percentage of the total gel absorbance. Relative 
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contributions within groups across multiple gels were then pooled, allowing for statistical analysis 
with the full experimental group sizes, instead of only within a single gel. This procedure prevents 
the systematic limitation in comparable group sizes that commonly confounds western blot 
analyses. 
39 
 
 
 
CHAPTER 3: STATINS AND MUSCLE FUNCTION 
Statins and Novel or Accustomed Exercise: Impacts on Skeletal Muscle 
Strength and Fatigue 
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INTRODUCTION: 
 HMG-CoA reductase inhibitors (statins) are a well-known class of drugs that are highly 
effective in reducing low-density lipoprotein levels and cardiovascular disease risk. They are also 
well-tolerated, with a low overall incidence of side effects, and this combination of efficacy and 
safety has led to common prescription, which is expected to continue increasing in the future 
alongside a growing elderly population and the ongoing discovery of their pleiotrophic effects 
1
. 
Unfortunately, however, statin treatment is not without risk, and the most common side effect is 
some degree of skeletal muscle dysfunction, ranging from mild soreness or weakness to potentially 
fatal rhabdomyolysis. While the prevalence of myopathy in the general statin-treated population 
may be up to 10% 
1,7-9
, the risk of myopathy is estimated to range up to 25% in statin users who 
also exercise 
1,14,13
, and perhaps above 75% in statin-treated athletes 
15
. 
 The pathways underlying statin-associated myopathy in general are not yet understood, and 
the literature directly examining the pathways responsible for the exacerbation by exercise is 
extremely limited. Existing research has indicated that statin treatment prior to a damaging 
exercise bout can increase genes involved in protein catabolism in humans 
78
, while two weeks of 
concurrent statin treatment and treadmill running in rats has been shown to increase mitochondria 
and organelle damage, inflammatory cell infiltration, and structural damage 
43
.  
  With only a single exception 
43
, the current literature regarding statins and exercise has 
examined the impact of statin treatment on the muscle damage induced by a single bout of exercise 
78,69,66,62-65
. These studies commonly use 4 or more weeks of statin treatment prior to the exercise 
bout, with creatine kinase (CK) as a common measure of the damage response. Examination of the 
available literature reveals no investigations of deliberate exercise training or multiple exercise 
bouts prior to the initiation of statin treatment.  This presents a significant void in the literature, as 
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many rapid and long-term adaptations occur within skeletal muscle in response to both acute and 
chronic exercise stimuli 
92-94
. Consequently, the current literature cannot be assumed to translate to 
situations where exercise accustomization occurs prior to statin treatment.  
 Furthermore, many adaptations that occur in muscle with exercise training—such as 
reduced ultrastructural damage, increased heat shock protein (Hsp) expression, and improved 
metabolic function 
95,96,123,92-94—could be expected to protect against statin-induced muscle 
damage. Therefore, we hypothesized that the exacerbation of statin-induced myopathy by exercise 
may be specific to untrained muscle, and that exercise training prior to the commencement of 
statin treatment may be protective against subsequent damage. As such, the current study was 
designed to investigate the muscle damage associated with statin use in response to either novel 
and accustomed exercise. Additionally, muscle contractile function measures were used for the 
evaluation of muscle damage, presenting the first use of a physiological measure of muscle 
function in a randomized, controlled trial examining statins and exercise. Furthermore, as a reliable 
measure of muscle damage, muscle force measures were used to examine the usefulness of blood 
CK levels as an indirect marker of statin-induced myopathy. 
 
METHODS: 
Overview:  Eight-week old, male C57BL/6J mice (Jackson Labs) were used for all procedures. 
The intervention was designed to examine statin treatment in combination with novel or 
accustomed exercise, and to compare these conditions to sedentary mice.  Voluntary running wheel 
activity was used as the exercise model, and cerivastatin (1mg/kd/day) was used for statin 
treatment. Previous rodent research has shown this drug regimen to cause skeletal muscle 
myopathy at two weeks 
44,43
. Additionally, research from our own lab and others has shown two 
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weeks of running wheel activity to elicit protective adaptations in murine skeletal muscle 
123,127
. 
Fourteen days was therefore chosen as the duration for both statin and exercise treatments. 
 To accommodate both novel and accustomed exercise treatments, mice were subjected to a 
28-day intervention. During the first 14 days the mice received no statin or saline injections, and 
only the accustomed exercise groups had access to running wheels. Starting on day 15, mice in the 
novel exercise groups were given access to running wheels, and all mice began receiving daily 
injections of either cerivastatin or saline. Daily injections and 24h running wheel activity tracking 
continued until day 28. These treatments yield six distinct treatment groups (See Table 2.1).  
 
Statin Injections: Cerivastatin (Sequoia Research) was suspended in sterile saline at .25mg/ml 
and injected intraperitoneally daily at a dosage of 1mg/kg/day. Injections were given towards the 
beginning of the mice’s light (inactive) cycle to minimize the disturbance of running wheel 
activity. 
 
Running Wheel Activity: Mice were individually housed in cages equipped with running wheels 
(MiniMitter). These wheels are equipped with magnetic reed switches which were connected to 
bicycle computers (Sigma), allowing distance and time to be tracked continuously. Running wheel 
activity was recorded every 24 hours during the light cycle. Novel exercise group mice were 
transferred to running wheel cages on day 15 near the end of their light cycle, and so received their 
first statin injections ~8 hours before their first dark (active) cycle with running wheel access. 
 
Force Measurement: Measurements of hind-limb plantarflexor force-production ability were 
made on day 28, approximately 24hours after the previous statin injection. To perform these 
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measures, mice were fully anesthetized under ketamine/xylazine, and the sciatic nerve was 
dissected through the lateral thigh. The common peroneal branch was severed, allowing isolated 
activation of the plantarflexors by stimulation of the sciatic. The hindfoot was then placed on a 
plate attached to a servomotor able to measure applied torque and control ankle rotation (305C-LR, 
Aurora Scientific ). The sciatic nerve was then hooked by electrodes to a square wave stimulator 
(A-M Systems) and stimulated at 250hz for 1.5 seconds to evoke a maximum-force contraction. 
The servomotor was set to maintain position, ensuring that the contraction was isometric. With 5-
second delays between stimulations, the contraction was repeated 9 additional times in order to 
examine muscle fatigability. As a measure of fatigue, the 10
th
 contraction was compared to the 
maximum contraction, and expressed as a percentage of maximal force. 
 
Creatine Kinase: Immediately after force measurements, blood was drawn into EDTA-treated 
tubes, then centrifuged for 10 minutes at 1,200g and 4°C to extract plasma. Creatine kinase levels 
were measured by an activity assay (BioAssay Systems) as per the manufacturer’s instructions. 
 
Statistical Analyses: Running wheel activity was analyzed by the comparison of important time-
points. 3-day activity totals were calculated for each mouse for days 12-14, 15-17, and 26-28 and 
compared between saline/statin treatments by independent-samples t-test. Additionally, total Area 
Under the Curve (AUC) was also compared between saline/statin treatments. 
 Muscle force and plasma CK data were analyzed by separate multiple regression models 
including main effect terms for injection and exercise, as well as a term for injection*exercise 
interactions. Running wheel distances were also examined as a possible covariate for the muscle 
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force and plasma creatine kinase regression models. Tukey post-hoc analysis was performed to 
examine specific group differences only if a significant interaction or main effect was found.  
 Finally, Pearson correlation tests were performed to examine correlations between running 
wheel activity, muscle strength, and plasma CK within activity groups. All analyses were 
performed with SPSS v.15 statistical software (IBM) with alpha set at 0.05. 
 
RESULTS: 
General: No significant group differences were found at the end of the intervention for 
bodyweight. One mouse in the Novel/Saline group died due to unknown causes, leaving n=9 for 
this group and n=10 for all other groups. 
 
Running Wheel Activity: No significant differences in wheel activity were found between saline 
and statin-treated groups for any of the three 3-day totals or for activity AUC (Figure 3.1).  
 
Muscle Force:  A significant regression model (ƒ(3,55)=19.4, p<0.000, R=0.72) was found for 
muscle force, and a significant injection by activity interaction effect (p<0.05) was found for 
maximal isometric force-production. Statin-treated mice showed reduced isometric force as 
compared to their saline controls in both the sedentary and novel exercise groups (15% and 27% 
reduction, respectively), while the statin-treated accustomed exercise group showed no reduction 
in force (Figure 3.2). A significant model (ƒ(3,55)=4.9, p=0.004, R=0.46) was also found for 
muscle fatigability, including a significant injection by activity interaction (p<0.05), with both the 
sedentary and novel exercise statin-treated groups showing reduced isometric force-production on 
the 10
th
 contraction (51 and 54% maximum-force, respectively) as compared to their respective 
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saline-treated groups (62 and 70% maximum, respectively). Mice in the accustomed exercise 
groups finished at 67 and 69% maximal isometric force for the saline and statin groups, 
respectively. No significant group differences were found for gastrocnemius muscle weights. 
Inclusion of running wheel activity as a covariate did not significantly affect the regression model 
for maximal force production or fatigability. 
 
Creatine Kinase:  No significant main effects for injection or activity were found for plasma CK 
(Table 3.1).  
 Table 3.1 
Plasma Creatine Kinase (U/L) 
Injection Sedentary Novel Ex. Accust. Ex. 
Saline 142.8±14.1 131.1±19.5 146.8±13.3 
Statin 133.4±17.0 126.8±17.6 145.6±16.7 
Table 3.1: Plasma creatine kinase levels by group. No significant effects of injection or activity 
were found. 
 
Outcome Correlations: 
Between the three running wheel time-points, isometric muscle force, and plasma CK, no 
significant correlations were found. 
46 
 
 
FIGURE 3.1: RUNNING WHEEL ACTIVITY 
 
Figure 3.1:  Average daily voluntary running wheel activity (+/- SE) in Accustomed (A) and Novel 
(B) exercise groups. Analysis of 3-day distance totals for days 12-14, 15-17, and 26-28 
revealed no significant group differences for either activity treatment.  
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FIGURE 3.2: MAXIMAL FORCE PRODUCTION 
 
Figure 3.2: Hind-limb plantarflexor strength in sedentary, novel exercise, and accustomed exercise 
mice after 4 weeks normal cage activity (sedentary), two weeks normal cage activity and 
two weeks running wheel access (Novel), or 4 weeks running wheel access (Accustomed), 
with saline or cerivastatin (1mg/kg) during the final two weeks of treatment. A significant 
activity by injection interaction was found for strength, with significant force decrements 
in the sedentary mice, increased force loss with novel exercise, and force preservation with 
accustomed exercise.  Means+SE. *P<.05 vs. corresponding saline group. 
 
DISCUSSION: 
 A variety of previous reports have confirmed that statin-induced myopathy is exacerbated 
by physical activity or exercise, with activity raising the risk for myopathy by greater than 100% 
1,14,13
. We investigated the hypothesis that statin-associated muscle damage is greater in response 
to novel exercise compared to accustomed exercise.  Specifically, training –induced muscle 
adaptations may protect muscle from the deleterious interactions between statin treatment and 
exercise. This study is the first known examination of exercise accustomization prior to the 
commencement of statin treatment, contributing significant new knowledge regarding 
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statin/exercise interactions in regards to myopathy. Additionally, a reliable and functional measure 
of muscle damage—isometric force—was used for the first time in a controlled statin/exercise 
intervention setting, allowing improved validity and physiological relevance in myopathy 
assessment as compared to indirect markers such as blood creatine kinase levels. 
 As predicted, the statin-treated sedentary mice showed reduced isometric force production 
compared to the saline-treated controls, indicating that cerivastatin at 1mg/day causes 
physiologically relevant myopathy in sedentary mice, which is consistent with previous 
histological reports of this same intervention in rats 
44,43
. Additionally, statin treatment was 
associated with even greater decrements in isometric force in the novel exercise group, 
demonstrating exacerbation of statin-induced myopathy in response to novel exercise. This is also 
consistent with previous histological evidence of exacerbated myopathy in rats undergoing two 
weeks of treadmill running while receiving cerivastatin treatment. Specifically, the muscles of rats 
receiving cervistatin while running showed elevated mitochondrial damage, increased 
inflammatory cell infiltration, and disorganized myofiber structure 
43
. Most significantly, our 
accustomed exercise group showed no decrements in muscle force with the introduction of statin 
treatment, presenting the novel finding that two weeks of prior running wheel activity is protective 
against both statin-associated decrements in muscle function and its exacerbation by exercise.   
 While the daily average wheel-running distances for the novel/statin group were 
consistently lower than the daily distance for the novel/saline group, no significant statistical 
differences were found between these groups due to high individual variability (Average SD for 
24h distances: 2290 and 1960 meters for novel/saline and novel/statin groups, respectively). 
However, based on previous literature examining differences in susceptibility to statin-induced 
damage between type I and type II muscle fibers, these results are not unexpected. Prior reports 
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have shown that type II fibers—the greatest contributors to maximal muscle force—are susceptible 
to statin-induced damage, while Type I fibers—which would be most important for running wheel 
activity—are protected 44,83,84,43.  
 Due to these apparent differences in susceptibility between fiber types, it was not expected 
that the statin-treated mice would show an increase in fatigability—when expressed as a 
percentage of maximum—as type I fibers would likely represent a greater percentage of initial 
force in myopathic muscle. It is interesting to note, however, that the sed/statin and novel/statin 
groups showed significant increases in fatigability, which indicates potentially severe inabilities to 
cope with the stresses of repeated activation, likely in type II fibers. Hypothetically, given two 
muscles of equal size and fiber-type distribution, if one muscle suffers type II fiber damage and 
dysfunction, this muscle could be expected to complete the current isometric protocol at a higher 
percentage of initial contraction than the undamaged muscle, though at a lower absolute strength. 
This would assume that the damaged type II fibers either do not contribute to force production, or 
contribute but fatigue at a relative rate similar to that of healthy fibers. Up to a point, increased 
fatigability in damaged type II fibers would only serve to increase overall fatigability in this 
damaged muscle back towards that of the undamaged muscle. Therefore, the elevated fatigability 
in the sed/statin and novel/statin groups indicates that either type I fibers have been affected, or 
that damaged type-II fibers are still contributing to force production, but their ability to recover 
from contractions has been significantly compromised.  
 Despite the significant reductions in isometric force observed with statin treatment in both 
the sedentary and novel exercise groups, plasma creatine kinase levels were not elevated by statin 
treatment.  In addition, plasma CK levels did not significantly correlate with running wheel 
activity or isometric force. A number of prior reports have demonstrated that statin-associated 
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myopathy can manifest without increases in CK levels 
75,76,60,77,7
, and the current findings in the 
sedentary groups support this. Additionally, the data from the novel exercise groups indicates that 
CK levels are also not sensitive to the exacerbation of statin-associated myopathy with exercise. 
Together, these findings present a strong case against the sole use of CK as a measure of statin-
induced myopathy—whether examined in combination with exercise or not—and indicate that 
literature using CK as a marker may underestimate the prevalence of myopathy.  
 The mechanisms underlying statin-associated skeletal muscle myopathy are not well 
understood, however several implicated pathways could be exacerbated by exercise. Mitochondrial 
dysfunction has been implicated in general statin-associated myopathy 
59,43
, and mitochondrial 
damage can be increased by the combination of statin-treatment and exercise 
43
. In the current 
findings, the increased fatigability shown with statin-treatment suggests that some metabolic 
dysfunction may be present. However, the short-duration, high-intensity nature of the fatigue test 
and the absence of differences in running wheel activity indicate that any significant metabolic 
disturbances induced by the current intervention are more likely to be in glycolytic or high-energy 
phosphate pathways, rather than mitochondrial oxidative pathways. Nonetheless, it is possible that 
statin-induced mitochondrial damage could have indirect effects on a short-term measure such as 
the current protocol. In the only other study to perform a controlled examination of statins’ effects 
on muscle strength, it was concluded that statin-induced mitochondrial dysfunction can lead to 
disruptions in calcium homeostasis, which was associated with decreases in voluntary strength and 
increased fatigability in the forearms of sedentary rats 
128
.  
 Another proposed mediator of statin-associated myopathy is a reduction in membrane 
fluidity due to reduced cholesterol availability, which has been shown to be a concern with 
cholesterol-lowering medications such as niacin and clofibrate 
45,46
.  However, reduced membrane 
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fluidity has not been implicated in statin-associated myopathy, and reducing cholesterol synthesis 
downstream of mevalonate—at squalene synthase—does not induce myopathy 47,48.  This suggests 
that reduced cholesterol levels are not directly responsible for statin-associated myopathy under 
sedentary conditions. However, membrane fluidity has not been examined with exercise, so it 
remains possible that membrane fluidity is reduced with statin-treatment and that this reduction 
does not cause pathology without the additional mechanical stressors of exercise. Conversely, 
while membrane fluidity was not directly examined in the current study, the absence of increased 
plasma CK in both sedentary and exercised statin groups indicates that membrane integrity was not 
compromised, despite significant reductions in muscle contractile function. 
 Further investigation is required to examine the mechanisms behind the protective effects 
of exercise training observed in the present study. As mentioned, skeletal muscle makes 
adaptations to both acute and chronic exercise stimuli, and many of these adaptations might be 
expected to protect muscle contractile function during statin treatment. For instance, our laboratory 
has previously shown that the 2-week running wheel intervention used in this study is associated 
with significant up-regulation of heat shock proteins in active muscles 
123
.  These stress proteins 
have been shown to be protective against a diverse array of stressors, including mechanical 
damage and reactive oxygen species 
97-104
.  In skeletal muscle, the Hsps have been shown to move 
to the cytoskeletal fraction after muscle contraction and potentially stabilize muscle structure, 
which would likely preserve contractile function.  Furthermore, in vitro data has indicated that 
statins can induce apoptosis in myotubes, myoblasts, and differentiated primary skeletal muscle 
cells 
35-38, and Hsp’s have been shown to inhibit apoptotic pathways 99,115-117, as well as show an 
inverse relationship to caspase-3 expression—an important marker of mitochondrially-mediated 
apoptosis—in some tissues 118-120.  
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 Further research is also required to determine the volume, frequency, or modality of 
exercise required to achieve protective accustomization in humans. In this study, the mice 
consistently ran upwards of 5 hours per day, presenting an impractical/impossible intervention for 
humans. However, the statin treatment was also severe, using a high dosage of cerivastatin—a 
drug that was removed from the market in 2001 due to unusually high incidence of serious 
myopathy. Therefore, the exercise training necessary to protect against the myopathy associated 
with current clinical statin prescriptions cannot be determined from the current study. However, it 
is reasonable to expect that less myopathic, more clinically realistic statin prescriptions would 
require less extensive exercise accustomization.  
 In conclusion, the current investigation represents the first known examination of exercise 
training prior to the initiation of statin treatment, and presents the novel finding that exercise 
accustomization is protective against statin-induced muscle damage, as well as the exacerbation of 
contractile dysfunction with exercise. These results present the encouraging and clinically 
important possibility that statin-induced myopathy and its exacerbation by exercise could be 
alleviated through carefully regimented exercise programs. Additionally, while statin-induced 
damage has been shown in both sedentary and exercised muscle by histological measures, these 
data present the first controlled confirmation of physiologically relevant deficits in muscle function 
and exacerbated functional losses in muscle subjected to novel exercise. Further, creatine kinase 
was shown to be completely insensitive to reduced contractile function in both sedentary and 
novel-exercise mice. In combination with previous research also indicating a lack of CK sensitivity 
to statin-associated myopathy, these findings indicate that previous literature utilizing CK may 
have underestimated the prevalence of myopathy, and strongly suggest against the use of CK as 
the sole marker of myopathy in both clinical and research settings. 
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CHAPTER 4: CELLULAR MECHANISMS 
The interactions of Statins and Novel or Accustomed Exercise and their impact 
on Skeletal Muscle Caspase and Heat Shock Protein Expression 
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Introduction: 
 HMG-CoA reductase inhibitors (statins) are a widely prescribed, effective, and generally 
safe class of drugs, used to lower cholesterol levels and reduce the risk of cardiovascular disease. 
With the ongoing discovery of pleiotropic effects and the increasing elderly population, their 
future prescription is expected to continue increasing 
1
. The most common of these is some degree 
of skeletal muscle myopathy, ranging from potentially fatal rhabdomyolysis to minor aches or 
weakness. While the risk for myopathy has been estimated at 1-10% in statin-users overall 
1,7-9
, the 
risk for myopathy is elevated to as high as 25% in those who are also exercisers 
1,14,13
, and may be 
as high as 75% in statin-treated athletes 
15
. The mechanisms responsible for statin-associated 
myopathy in general are not currently understood, and unfortunately, the potentially detrimental 
interaction with exercise has been sparsely researched. 
 While a number of studies have investigated the influence of statins on the skeletal muscle 
damage response to a single bout of exercise 
62-66,69,78
, few studies have mechanistically examined 
the exacerbation of statin-associated myopathy with exercise.  Additionally, to date only one study 
has examined the impact of repeated exercise bouts on statin-induced muscle damage 
43
. 
Furthermore, there are no data on the interactions between statin-induced myopathy and exercise 
when exercise training was performed prior to the initiation of statin treatment, i.e., the exercise 
stimulus given during statin treatment has always been a novel stimulus. This is especially 
problematic, as a variety of structural and metabolic adaptations occur in skeletal muscle in 
response to repeated exercise bouts, or even to a single novel bout 
92-94
. As a result, the literature 
addressing statins and exercise using novel exercise stimuli cannot be assumed to also apply to 
statins and accustomed exercise. 
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 Therefore, the aim of this study was to investigate the impact of both novel and accustomed 
exercise on molecular stress markers in skeletal muscle during statin treatment.  We chose to focus 
on two specific stress and damage activated markers in skeletal muscles: heat shock proteins 
(Hsps) and activated caspases—an apoptotic marker. The effect of statins on Heat shock protein 
expression in skeletal muscle has not previously been examined, and while statin-initiated 
apoptosis has so far been shown not to occur in vivo, it has not yet been examined with the 
combined treatments of statin and repeated exercise. 
 Within the large family of Hsp stress proteins, the effects and statins and exercise on two 
small Hsps—Hsp25 and αB-crystallin—was investigated, since both of these Hsps are associated 
with helping maintain muscle integrity with damaging contractions 
101
. While acute damaging 
exercise increases both large and small Hsps, only one study has characterized the response of the 
small Hsps Hsp27 and αβ-crystallin to non-damaging exercise, and the results suggest that muscle 
damage may be important for increases in Hsp27 and αβ-crystallin to occur, as only Hsp72 was 
increased in human skeletal muscle following a bout of non-damaging exercise 
129
. Numerous 
other studies have also indicated that a single bout of non-damaging treadmill exercise can 
increase Hsp72 in both humans and rodents 
130-133,129
. Therefore, small Hsps were chosen to be 
examined due to their possibly unique responses to and role in muscle damage. 
 For indicators of statins’ impact on apoptosis, the expression of caspase-9 and activated 
caspase-3 were chosen.  Caspases are proteases involved in both the initiation (caspase-8, -9, -12) 
and execution (caspase-3, -6, -7) of apoptosis. Importantly, caspase-9 is an activator of caspase-3, 
and the activation of caspase-3 is likely a critical rate-limiting step for myofilament release and is 
strongly implicated in accelerated contractile protein breakdown and muscle weakness 
39,40,134
, 
thereby positioning these as markers of especially high importance in skeletal muscle.  Hsp25 or 
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αβ-crystallin over-expression in non-muscle tissues has been shown to significantly reduce 
caspase-3 activity in vivo 
120,118
 and in vitro 
135-137
 likely by inhibiting the cleavage of pro-caspase-
3 into active caspase-3 
136,138
. Additionally, hsp25 has been shown to inhibit the cleavage of 
procaspase-9 into active caspase-9 
139
. Therefore, caspase-9 and caspase-3 present interesting 
points to examine the apoptotic cascade, due both to their position near the end of the apoptotic 
pathway and subsequent importance to the execution of apoptosis in skeletal muscle and to the 
potential for exercise and muscle damage to affect their expression via the Hsps of interest. 
 It was hypothesized that statins would cause a reduction in the heat shock proteins hsp25 
and αB-crystallin, and may increase the apoptotic markers caspase-3 and caspase-9. Further, it was 
predicted that these changes would be exacerbated by novel exercise while undergoing statin 
treatment. Alternatively, it was predicted that exercise training prior to the initiation of statin 
treatment would be protective against—and perhaps reverse—the changes seen in sedentary and 
novel exercise groups, and that elevated hsp expression due to exercise would be associated with 
reductions in caspase expression. 
 
METHODS: 
Overview:  This intervention was designed to compare the effects of statin treatment between 
sedentary, novel exercise, and accustomed exercise mice. C57BL/6J mice (Jackson Labs) were 
used for all procedures, and were 10 weeks old at the initiation of statin treatment. 60 total mice 
were used, with n=10 for all groups. 
 A four-week intervention, divided into two halves was used. Sedentary mice (Sed/Saline 
and Sed/Statin groups) remained in standard cages from days 1-28, and received statin/saline 
injections from days 15-28. Novel exercise mice (Novel/Saline and Novel/Statin) were in standard 
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cages from days 1-14, but were then transferred to running wheel cages on day 15 and received 
injections from days 15-28. Accustomed exercise groups (Accust/Saline, Accust/Statin) were 
housed in running wheel cages from days 1-28, and received injections from days 15-28 (See 
Table 2.1).  
 
Running Wheels:  Exercising mice were individually housed in running wheel cages (Mini-
Mitter) with continuous access to their wheels.  Accustomed exercise mice had running wheel 
access days 1-28, while novel exercise mice had running wheel access days 15-28. Two weeks was 
chosen as the accustomization and exercise period as research from our own lab and others has 
shown two weeks of running wheel activity to initiate exercise adaptations in skeletal muscle, 
including upregulations in the hsps of interest to the current investigation 
123,127
. 
 
Statin Injections:  Beginning on day 15, cerivastatin or saline intraperitoneal injections were 
given every 24 hours until day 28. Cerivastatin (Sequoia Research) was dissolved at .25mg/ml in 
sterile saline and injected at 1mg/kg/day via a single injection. Injections were given towards the 
beginning of the mice’s light cycle to minimize any direct effects on running wheel activity. 
Cerivastatin was the statin of choice due to its unusually high incidence of muscle side effects, and 
the fact that previous interventions have shown this dosing to consistently cause myopathy at 2 
weeks 
44,43
.  
 
Western Blotting: Western blots were performed to analyze muscle expression of hsp25, αB-
crystallin, caspase-3, and caspase-9. The gastrocnemius was excised on day 28 and mechanically 
homogenized in a buffer containing 50mM Tris-HCl (pH 7.8), 2 mM potassium phosphate, 2 mM 
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EDTA, 10% glycerol, 1% Triton X-100, 1 mM dithiothreitol, 3 mM benzamidine, 1 mM sodium 
orthovanadate, 10 mM leupeptin, 5 mg/ml aprotinin, and 1 mM 4-[(2-aminoethyl) benzenesulfonyl 
fluoride], and supplemented with protease and phosphatase inhibitors (Sigma). Homogenates were 
immediately centrifuged at 12000g at 4°C for 12 minutes, after which the supernatant—the 
detergent soluble fraction—was removed. Protein concentrations were determined by Bradford 
assay (Biorad) using a bovine serum albumin standard curve and immediately stored at -20°C for 
subsequent use in western blotting. For gel loading, 30μg of total protein was boiled in loading 
buffer for 5 minutes at 95°C. Proteins were separated by sodium dodecylsulfate–polyacrylamide 
gel electrophoresis (SDS-PAGE) (12.5%) and transferred to PVDF membranes (Millipore). After 
transferring, successful equal loading was confirmed by Ponceau-S staining. Only gels with equal 
loading were used for subsequent antibody staining and analysis. After Ponceau-S staining, 
membranes were blocked for a minimum of one hour in Tris-buffered saline (TBS) w/5% milk. 
After blocking, the blots were incubated overnight in primary antibodies (Hsp25 & αB-Crystallin, 
StressGen, 1:5000. Caspase-3, Upstate/Millipore, 1:1000. Caspase-9, Cell Signaling Technologies, 
1:1000) in TBS w/2.5% bovine serum albumin (BSA).  After primary antibody incubation, blots 
were washed three times with TBS/0.15% Tween, incubated in anti-rabbit IgG secondary antibody 
(Amersham Biosciences) at 1:5000 for one hour. After the secondary antibody the membranes 
were washed 3x in TBS/0.15% Tween, and developed using enhanced chemiluminescence 
(Amersham Biosciences) detected by CCD camera (Fujitsu). Blot images were analyzed using 
ImageQuant software (GE Healthcare). 
 
Statistical Analyses: Western blot data for each protein was analyzed by a separate multiple 
regression model including main effect terms for exercise and injection and the injection by 
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exercise interaction. If significant main or interaction effects were found, Tukey post-hoc tests 
were performed to examine appropriate group differences. All tests were performed with SPSS 
v.15 statistical software (IBM), with alpha set to 0.05. 
 
RESULTS: 
Heat Shock Protein Expression: Regression models were significant for both Hsp25 
(ƒ(3,55)=13.4, p<0.001, R=0.75) and αB-Crystallin (ƒ(3,55)=4.63, p=0.001, R=0.55). No 
significant exercise by injection interaction was found for Hsp expression, however significant 
main effects (P<0.05) for exercise were found for both Hsp25 and αB-crystallin, with both novel 
and accustomed exercise increasing expression as compared to the sedentary groups (Figure 4.1). 
No significant effect was found for statin injection. 
 
Caspase Expression: A significant model was found for caspase-9 expression (ƒ(3,53)=3.31, 
p=0.026, R=0.40), including a significant activity by injection interaction, with statin treatment 
increasing caspase-9 expression in the sedentary and novel exercise groups, but decreasing 
expression in the accustomed exercise group. Post-hoc tests did not indicate any individual group 
differences (Figure 4.2). Caspase-3 was not expressed at detectable levels in any group. Blots 
including caspase-3 positive controls (Cell Signaling Technologies) were used to confirm antibody 
specificity.  
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FIGURE 4.1: HSP PROTEIN EXPRESSION  
 
Figure 4.1: Expression of the heat shock proteins Hsp25 and αB-crystallin in the gastrocnemius after 
two weeks of statin/saline injections under sedentary, novel exercise, and accustomed 
exercise conditions. A significant main effect for activity was found for both Hsps, with 
both the novel and accustomed exercise groups showing significant elevations in 
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expression. Statin treatment was not found to significantly influence expression under 
any activity condition. 
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FIGURE 4.2: CASPASE-9 PROTEIN EXPRESSION 
 
Figure 4.2: Gastrocnemius caspase-9 expression after two weeks of statin/saline injections under 
sedentary, novel exercise, and accustomed exercise conditions. A significant 
activity*injection interaction was found, with statin treatment increasing caspase-9 
expression in the sedentary and novel exercise groups, but decreasing expression in the 
accustomed exercise groups. No significant individual group differences were found. 
Active caspase-3 was not detectable in any group; positive control shows Jurkat cells 
treated w/cytochrome-c to activate caspase-3. 
 
DISCUSSION: 
To our knowledge, this study presents the first examination of the influence of exercise 
novelty and accustomization on the skeletal muscle stress-response to statin treatment, and 
complements our previous work examining muscle function following this intervention (See Chap. 
3). Specifically, these data are the first in vivo examination of the effects of statin treatment and/or 
exercise on heat shock protein expression in skeletal muscle, and of exercise and statins’ influence 
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on apoptotic markers beyond a single exercise bout. Currently, the majority of the available 
literature regarding statins and exercise investigates a statin-potentiated damage response to a 
single exercise bout, rather than an exercise-induced exacerbation of statin-associated myopathy, 
though the line between the two phenomena is currently unclear. This study sought to address this 
shortcoming by utilizing repeated exercise bouts during statin treatment, as well as investigating 
the influence of exercise accustomization prior to the initiation of statin treatment, which had not 
been previously examined. 
Heat Shock Proteins: 
 Heat shock proteins have been shown to protect against a number of cellular stressors, 
including oxidative stress 
98
 and apoptosis 
99,115-117
, and may protect against mechanical damage in 
skeletal muscle 
100-104
. Interestingly, heat shock protein expression is higher in muscle fibers of 
primarily type I myosin heavy-chain composition 
105-109—which have been shown to be protected 
from statin-induced damage—and can also be increased by exercise, including following two 
weeks of wheel running, as used in the current intervention 
123
. The effects of statin treatment on 
hsp expression have been shown to vary by tissue 
110-114
, and the effect in muscle has not been 
previously examined.  Taken together, the existing knowledge on the functions of Hsps in muscle 
and the fact that their expression can be modulated with exercise suggests that Hsps may 
contribute to the previously reported protective effects of exercise accustomization against statin-
induced decrements in force-production ability (See Chap. 3). 
 In the current intervention, statin treatment was found to have no significant effect on 
hsp25 or αB-crystallin expression, regardless of activity condition, indicating that unlike many 
other tissues, statins do not affect small Hsp expression in skeletal muscle within the currently 
investigated time frame. Both novel and accustomed exercise treatment showed elevated Hsp 
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expression as compared to the sedentary groups, indicating an elevation in Hsp expression with 
exercise, though there were no differences between novel and accustomed exercise groups at four 
weeks, i.e. no difference between 4 weeks of running and 2 weeks. However, the elevated Hsp 
levels in the saline-treated, novel exercise group is of specific importance, because if the effect of 
saline injections on muscle Hsp expression is assumed to be negligible, this should also reflect the 
Hsp levels present in the accustomed exercise groups at the initiation of statin treatment. This 
indicates that while statin treatment does not appear to affect muscle Hsp levels, Hsp elevations 
present at the initiation of statin treatment may be protective against statin-associated myopathy 
and its exacerbation by exercise.  
 Further data concerning the time-courses of statins’ myopathic effects and of Hsp 
upregulation with running wheel exercise would be of interest in examining the novel exercise 
groups’ responses. The current results would indicate that while statin treatment did not prevent 
the upregulation of heat shock proteins during novel exercise training, this upregulation was not 
protective against myopathy. Further investigation is needed to determine why this is the case, 
though several possibilities can be hypothesized. Most significantly, it is possible that the Hsp 
upregulations seen with exercise—while associated with maintaining muscle integrity—are in fact 
not directly involved in exercise training’s protective effects. Directed investigations utilizing 
muscle-specific Hsp overexpression and/or deletion are needed to address this question. 
Alternatively, statin treatment may have caused the observed reductions in muscle force in the 
novel-exercise mice prior to the exercise-induced upregulation of Hsps, which would explain the 
current results if myopathy is preventable but not reversible by Hsp expression, or not reversible 
within the intervention timeframe. Currently, data addressing the time courses of exercise/statin 
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interactions are not available, therefore, it is impossible to determine what changes may have been 
seen with a shorter or longer exercise intervention.  
Caspases and Apoptosis: 
 Statins have been shown to induce apoptosis in a variety of cell types, including smooth 
muscle and cardiac myocytes 
24-33
. Additionally, in vitro and ex vivo research has demonstrated 
that myotubes, myoblasts, and primary human muscle cells are also susceptible 
35-38
. Further, the 
apoptosis shown in skeletal muscle cells has been shown to progress via caspase-dependent 
pathways, as statin-induced apoptosis is accompanied by elevations in caspase-9 and caspase-3 
35,38
. Activation of caspase-3 is especially important in examining the apoptosis of skeletal muscle, 
as the ubiquitin-proteasome system cannot split actinomyosin complexes, and caspase-3 is likely 
the rate-limiting factor in myofilament breakdown and therefore likely involved in muscle 
breakdown and weakness 
39-41
.   
 While numerous studies have shown that statins can induce apoptosis in vitro, few studies 
have examined the effects of statins on skeletal muscle apoptosis in vivo, though the results have 
consistently indicated that in vivo apoptosis does not occur 
42,43
. In one examination, clinic patients 
with statin-associated myopathy were found to have no indication of muscle apoptosis based on 
TUNEL staining, Bax, Bcl-2, and caspase-3 expression 
42
. While Bax—a pro-apoptotic protein—
and Bcl-2—an anti-apoptotic protein—are only intermediates in apoptotic signaling, TUNEL 
staining detects DNA that has been fragmented due to apoptotic processes, and therefore presents a 
measure of ongoing or recent apoptotic activity. In another examination of in vivo apoptosis, 
treatment of rats with 1mg/kg/day of cerivastatin for two weeks was not shown to increase muscle 
caspase-3 expression 
43
. While skeletal muscle appears to be resistant to statin-induced apoptosis 
in vivo, the exacerbation of statin-associated myopathy by exercise indicates that ruling out in vivo 
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apoptosis also requires careful examination of apoptosis under the combined treatments of statins 
and exercise.  However, the only prior study investigating statins and apoptosis in combination 
with exercise was indirect, as it only examined the human gene response to a single bout of 
damaging exercise after four weeks of atorvastatin treatment. Interestingly, the investigators 
actually found reduced expression in apoptotic genes in the statin-treated group eight hours after 
exercise, though unfortunately the specific genes involved were not discussed 
78
.  
In vitro research has shown that statins increase the expression of caspase-9 and activated 
caspase-3 during the apoptosis of myotubes and myoblasts 
35,38
, and in the current study statin 
treatment increased in vivo caspase-9 expression in the sedentary and novel exercise groups. In 
contrast, expression was decreased in the accustomed exercise group, indicating that exercise 
accustomization may block or even reverses statin’s activation of apoptotic pathways.  An 
upregulation in Hsp expression with exercise may be responsible for this interaction, as Hsp’s—
including hsp25—have been shown to inhibit the cleavage of procaspase-9 into the active subunit 
caspase-9, which was measured in the current study 
140,139
. Therefore, an elevation in muscle hsp 
expression after two weeks of wheel running may have inhibited any elevations in caspase-9 
activity by statin treatment. 
Caspase-9 is an activator of caspase-3; however, since activated caspase-3 expression was 
undetectable, it is difficult to say what physiological impact—if any—this reduction in caspase-9 
expression with exercise may have, as the activated caspase-3 data indicates that repeated exercise 
during statin treatment does not lead to in vivo skeletal muscle apoptosis. This is in agreement with 
previous research showing that statins do not induce in vivo apoptosis in sedentary muscle or 
muscle exposed to a single exercise bout 
42,43,78
. However, the lack of active caspase-3 expression 
in the novel-exercise group is an important confirmation, as the novel exercise intervention was 
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previously shown to be especially damaging as compared to sedentary statin treatment (See Chap. 
3), and this presents the first investigation of statin-associated myopathy and apoptosis with 
repeated exercise. Combined with the prior in vivo research, the current data indicate that statin 
treatment does not induce in vivo skeletal muscle apoptosis, be it in sedentary or exercised muscle.  
In conclusion, this study presents a novel investigation into the impact of statin treatment 
on skeletal muscle expression of Hsp25, αB-crystallin, caspase-9, and caspase-3 in mice 
completing repeated novel or accustomed exercise. The results indicate that while statin treatment 
increases caspase-9 expression in sedentary and novel-exercise muscle, this effect is reversed in 
the muscle of mice undergoing exercise accustomization prior to the initiation of statin treatment. 
However, the caspase-3 data indicate that the combination of statin treatment and repeated 
exercise—even the novel exercise intervention, which has been shown to be especially damaging 
to skeletal muscle—does not lead to an increase in apoptosis in vivo. This is in agreement with 
previous literature indicating that statins do not induce in vivo apoptosis in sedentary muscle or 
muscle exposed to a single exercise bout. Additionally, we have found that an upregulation in 
Hsp25 and αB-crystallin expression after two weeks of wheel running presents a possible 
mechanism for the previously demonstrated protective effects of exercise accustomization, though 
further investigation is necessary to examine the causal role for Hsps. 
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APPENDIX 
Prior Work Regarding Muscle Function and Interventions to Preserve/Restore 
Reduced Function 
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GLUTAMINE PRESERVES SKELETAL MUSCLE FORCE DURING 
AN INFLAMMATORY INSULT* 
BENJAMIN M. MEADOR, BA and KIMBERLY A. HUEY, PhD 
 
Abstract: 
Purpose: To test the hypothesis that acute Glutamine (GLN) supplementation can counteract 
skeletal muscle contractile dysfunction occurring in response to inflammation by elevating muscle 
heat shock protein (Hsp) expression and reducing inflammatory cytokines. Methods: Mice 
received 5mg/kg Lipopolysaccharide (LPS) concurrently with 1g/kg GLN or vehicle treatments. 
Plantarflexor isometric force-production was measured 2 hours post-injection. Blood and 
gastrocnemius muscles were collected, and serum and muscle Tumor Necrosis Factor-alpha 
(TNFα) and Interleukin-6 (IL-6) and muscle Hsp70 and Hsp25 were quantified. Results: 
Saline/LPS-treatment was associated with a 33% reduction in maximal force and elevated serum 
TNFα and IL-6. GLN completely prevented this force decrement with LPS. GLN was found to 
reduce muscle Hsp70 and IL-6, but only in the presence of LPS. Conclusion: GLN 
supplementation provides an effective, novel, clinically applicable means of preserving muscle 
force during acute inflammation. These data indicate that force preservation is not dependent on 
reductions in serum cytokines or muscle TNFα, or elevated Hsp levels. 
 
 
* This manuscript has been previously published and can be accessed by the below reference. Its 
current use has been permitted by the original publisher. 
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Introduction 
 Chronic and acute inflammatory diseases—such as chronic cardiopulmonary disease, 
cancer, transplant rejection, and sepsis—are often associated with respiratory and skeletal muscle 
weakness 
141-145
, which typically correlates with a loss of muscle protein 
141,146,142,147
. The 
decrements in muscle function under these conditions are believed to be mediated in part by 
elevation of the catabolic cytokines Tumor Necrosis Factor alpha (TNFα) and interleukin-6 (IL-6) 
144
. However, it has also been demonstrated that inflammatory disease can cause reductions in 
muscle strength without muscle protein catabolism 
148-151
. The mechanisms behind contractile 
dysfunction in the absence of muscle wasting are not well understood, though some loss of 
contractile regulation has been indicated 
144
. Both with and without muscle wasting, TNFα—which 
is known to be elevated in several inflammatory diseases 
152-158
 and has been shown to 
independently, acutely reduce contractile function 
159-161,144,162,163—is likely a key cytokine 
involved in contractile dysfunction. Additionally, IL-6 has been implicated in some chronic 
conditions of muscle atrophy and strength loss such as chronic cardiopulmonary disease and 
cancer, where muscle wasting is a significant factor 
164-169
. Regardless of the etiology, contractile 
dysfunction presents a clear hindrance to physical function in individuals with these chronic 
diseases, and it is a potential obstacle to rapid recovery and rehabilitation after surgical 
complications of infection or even sepsis. 
In this study we examined the potential role for glutamine (GLN) supplementation in 
counteracting contractile dysfunction during an inflammatory insult. GLN is a non-essential amino 
acid that plays critical roles in immune system function and skeletal muscle protein turnover. 
During stressful events, such as systemic sepsis, the body’s natural ability to synthesize GLN is 
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impaired, which has led to it being known as a conditionally essential amino acid 
170
. GLN 
supplementation has been found to improve clinical outcomes during sepsis 
171
, and these 
improvements have been related to increases in heat shock protein (Hsp). Hsp70 expression is 
increased in non-skeletal-muscle tissues such as the lungs, heart, kidney, and colon 
170
, and 
increases in Hsp25 expression in the heart, liver, and colon
170
, as well as reductions in systemic 
inflammatory mediators, namely NF-ΚB and TNF-α 172 are also found. GLN’s effects on Hsp 
expression in skeletal muscle during an inflammatory insult have not been examined. It has been 
shown that GLN supplementation can increase Hsp70 expression in myotubes exposed to heat 
stress 
173
. If GLN has similar affects in mature skeletal muscle as in these other tissues, it would 
have the potential to upregulate expression of Hsp25 and Hsp70. Such an effect in response to a 
contractile dysfunction-inducing inflammatory insult would have the potential to help preserve 
muscle function, as these Hsp’s have been shown to have protective effects against heat stress 174, 
oxidative stress 
175-178
, apoptosis 
179-182
, and muscle damage 
183,184,102
. 
Since skeletal muscle is by far the largest contributor to plasma GLN levels 
185
, the 
―conditionally essential‖ classification of GLN would indicate that these systemic inflammatory 
events drastically affect skeletal muscle protein metabolism. Still, to our knowledge, the effects of 
GLN supplementation on skeletal muscle during an inflammatory insult have not been examined. 
The purpose of this study is to examine the effects of GLN supplementation on muscle strength, as 
well as serum and muscle cytokine levels and muscle Hsp70 and Hsp25 expression during acute 
inflammation induced by lipopolysaccharide (LPS) administration. It is hypothesized that, in 
response to an acute inflammatory insult, GLN supplementation will preserve muscle strength and 
endurance and that this will be associated with reduced levels of muscle and serum inflammatory 
cytokines, primarily TNF-α, and increased expression of Hsp70 and Hsp25 in muscle.    
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Methods 
A total of 29 C57BL/6J mice (Jackson Labs), aged 8-10 weeks were used in these studies. 
For the first set of experiments, 21 mice were randomly assigned to one of the following groups: 
Saline/Saline (n=5), Saline/LPS (n=5), GLN/Saline (n=5), and GLN/LPS (n=6). Saline was the 
vehicle for both GLN and LPS.  LPS-group mice received I.P. injections of 5mg/kg E. Coli LPS 
(Sigma, serotype 0127:B8) in a 0.5mg/ml saline solution. Dose-response experiments with LPS (1 
mg/kg, 2.5mg.kg, 3.5mg/kg, & 5mg/kg) found that a dose of 5mg/kg was necessary to induce 
reductions in muscle force without inducing sepsis. The GLN groups received I.P. injections of 
1g/kg GLN (HyClone) (.05g/ml) in saline suspension. The dose of GLN was chosen based upon 
previous studies that showed positive effects when 1g/kg or higher of I.P. GLN were used 
186,187
.  
Saline or LPS and Saline or GLN injections were given concurrently. Concurrent injections were 
chosen over pre-treatment with GLN to increase the clinical applicability of the intervention. Force 
measurements were taken 2 hours post-injection, and muscles and blood were immediately isolated 
as described below.  
A later time-point (24h) utilizing a lower dosage (1mg/kg) was examined using 8 additional 
mice divided into three treatment groups: Saline/Saline (n=2), Saline/LPS (n=3), and GLN/LPS 
(n=3). These mice were used to examine time-dependent changes in Hsp expression. They 
received a lower LPS dosage, as the 5mg/kg LPS dose used at the 2-hour time-point corresponds to 
approximately LD50 in this strain of mice. LPS mortality occurs ~18-22 hours post-injection, 
therefore the lower dosage was selected to avoid LPS-induced mortality at the 24-hour time-point. 
Force was not measured in these groups, as preliminary experiments found that this lower dose of 
LPS was not associated with any significant decrements in muscle isometric force.  These 
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experiments were approved by the Animal Use Committee at the University of Illinois and 
followed the American Physiological Society Animal Care Guidelines. 
Force Measurement: An in vivo force system similar to previously described models
188
 
was developed for these measurements. Specifically, all mice had measurements taken for the 
maximum isometric contraction strength of the hindlimb plantar flexors. Force was measured 
using a dual-mode lever system, which controlled both length and force/speed (Aurora Scientific, 
305C-LR). The servomotor system was calibrated by placing known weights 20mm from the 
rotational axis and creating a torque/voltage standardized curve.  
Mice were fully anesthetized by the administration of 100mg/kg Ketamine/10mg/kg 
Xylazine IP. Mice were then placed on a table warmed to 37°C, where all further procedures were 
done. An incision was made in the lateral thigh, parallel and superficial to the femur, through 
which the sciatic nerve branch innervating dorsiflexors was transected to allow isolated contraction 
of the plantarflexors. Two electrodes were placed proximal to the gastrocnemius complex on the 
sciatic nerve, with the two electrodes approximately 1mm apart. The ankle of the mouse was fixed 
in the servomotor’s footplate, with the talus (rotational center of the ankle joint) aligned with the 
servomotor axis. The mouse was positioned to place the knee joint at 90° and the ankle at 80°, 
where the knee joint was immobilized with an alligator-clip at the femoral condyle. The sciatic 
nerve was stimulated at 200hz for 1.5s to evoke a maximal contraction. This stimulation was 
repeated nine times with a recovery period of 5s, for a total of 10 measurements. The highest 
acquired data points were taken as the maximum. Fatigue was quantified by comparing the final 
contraction force to the maximal contraction and calculating a percent reduction. The exact timing 
of the force measurement in relation to the LPS and GLN injections (time-post) was recorded for 
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statistical analysis purposes. Data were recorded by a customized LabView program (National 
Instruments) to provide a plot of ankle-torque/time. 
Mice were euthanized immediately after the completion of the force-measurement protocol. 
Blood was drawn from the inferior vena cava, and the plantarflexors were isolated from the 
hindlimbs. The gastrocnemius was isolated from the soleus and immediately frozen on dry ice and 
stored at -80ºC. Muscles from the stimulated and non-stimulated limbs were divided for separate 
analysis. Unless otherwise noted, the muscle from the non-stimulated limb was used for analysis to 
ensure that stimulation itself did not affect variable outcomes. Whole blood was centrifuged at 
1500rcf for 10 minutes, and the serum was subsequently extracted and immediately stored at -
80ºC. 
Protein Isolation: Pre-weighed muscle samples (~40 mg) were homogenized in 10 
volumes of an ice-cold buffer containing 50mM Tris HCl (pH 7.8), 2 mM potassium phosphate, 2 
mM EDTA, 10% glycerol, 1% Triton X-100, 1 mM dithiothreitol, 3 mM benzamidine, 1 mM 
sodium orthovanadate, 10 mM leupeptin, 5 mg/ml aprotinin, and 1 mM 4-[(2-aminoethyl) 
benzenesulfonyl fluoride], and supplemented with protease and phosphatase inhibitors (Sigma) 
using a motor driven glass pestle. Homogenates were immediately centrifuged at 12,000 g for 12 
min at 4°C, and the supernatant was removed as the detergent-soluble fraction. Protein 
concentration was determined with the Biorad Protein Assay using bovine serum albumin for the 
standard curve, after which samples were saved immediately in aliquots at –80°C for subsequent 
use in ELISA analysis. 
 Cytokine Measurements: TNF and IL-6 measurements were performed on serum and 
muscle homogenate from the non-stimulated gastrocnemius using the Endogen ELISA kits (kits 
EMTNFA and EM2IL6, respectively), according to the manufacturer’s protocol as described 
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previously 
189
. Cytokine concentrations were expressed as pg/mg protein or pg/ml for muscle and 
plasma, respectively. 
Heat Shock Protein Measurements: Western blot analysis was used to determine Hsp25 
and Hsp72 protein levels in skeletal muscle. Twenty-five μg of detergent-soluble proteins were 
boiled (5 min at 95°C) and separated by one-dimensional sodium dodecyl sulfate polyacrylamide 
gel electrophoresis (SDS-PAGE) (12.5%) and transferred to nitrocellulose membranes (pore size 
45 μm). After protein transfer, the membranes were blocked for 1 hr in Tris buffered saline 
(TBS)/5% milk. Following blocking, the membranes were incubated overnight at 4°C with 
antibodies to detect Hsp25 (1:5000) or Hsp70 (1:5000) antibody in TBS/2.5% BSA. All antibodies 
were purchased from Assay Designs (Ann Arbor, MI). Blots were washed 3 times in 
TBS/0.1%Tween and incubated with anti-rabbit secondary antibodies (Amersham Biosciences, 
Piscataway, NJ, USA) at 1:5,000 for 1 hr at room temperature. Blots then were washed in 
TBS/0.1%Tween, and the bound antibodies were detected with enhanced chemiluminescence 
(Amersham Biosciences). Quantification of the bands was performed using ImageQuant Analysis 
software. All the necessary controls for Western blots were performed to assure antibody 
specificity. Equal loading was quantified with Ponceau S by densitometric analysis of 3 non-
specific bands prior to blocking and protein detection. Only gels with equal loading were used for 
subsequent quantification of specific proteins. 
 Statistical Methods: A separate 2x2 factorial ANOVA was performed for each variable of 
interest. The exact time of the force measurements in relation to the GLN and LPS injections was 
used as a covariate for all analyses. If a significant main effect or interaction was detected, post-
hoc analysis was performed by the LSD test to examine group differences. All calculations were 
performed with SPSS statistical software (v. 15), with alpha = 0.05.  
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Results: 
 No significant group differences in body weight at the time of force measurement were 
found 25.4±0.1, 25.6±1.0, 24.2±0.8, & 24.0±0.6 for Saline/Saline, GLN/Saline, Saline/LPS, & 
GLN/LPS groups, respectively). Additionally, while time-post varied slightly from animal-to-
animal due to anesthesia and surgery times, it ranged between 119 and 127 (mean 121.5) minutes, 
and was not significantly different between any groups.  
Force Measures: A significant Saline/GLN*Saline/LPS interaction effect was found for 
muscle force normalized to body weight (p=.001). Post-hoc analysis showed a significantly lower 
average force in the Saline/LPS group as compared to all three of the other groups by 
approximately 33% (Fig. 1). However, there was no significant difference in force outputs between 
any of the other three groups. Additionally, fatigue levels were not significantly different across 
groups (Fig. 1).  
 Cytokine Levels: Significant main effects of LPS were found in both the serum and 
muscle for TNFα, while a significant main effect for LPS on IL-6 was found only in the serum (all 
p<.05). Serum TNFα and IL-6 were found to be significantly elevated in the LPS groups as 
compared to the corresponding saline groups (Table 1). In muscle, TNFα levels were lower in the 
LPS groups as compared to the corresponding saline group. A significant Saline/GLN*Saline/LPS 
interaction was found for muscle IL-6 levels, with IL-6 in the GLN/LPS group found to be 
significantly lower than all other groups. 
 Heat Shock Protein Measures: For the 2h time-point, no differences in the expression of Hsp-
25 were found for any group. However, Hsp-70 showed a significant main effect for GLN 
treatment and a significant 47% reduction in the GLN/LPS group as compared to all other 
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groups. At 24h, Hsp-25 showed a significant 29% reduction in the GLN/LPS group as compared 
to the Saline/LPS group (0.11±0.02, 0.15±0.01, & 0.11±0.01 arbitrary units for the Saline/Saline, 
Saline/LPS, and GLN/LPS groups, respectively) (Figure 2). 
91 
 
FIGURE A.1: PLANTARFLEXOR FORCE 
 
Figure A.1. Changes in average maximal isometric plantarflexor force 2 hours after administration 
of LPS with or without glutamine (GLN). Saline (Sal) was the vehicle control for both 
LPS and GLN.  Total column height denotes maximal isometric force.  White inner 
columns denote contraction force at repetition 10, with the percentage of initial force at 
72, 72, 71, and 77% in the Sal/Sal, GLN/Sal, Sal/LPS, & GLN/LPS groups, respectively. 
*p<0.05 versus all other groups for maximal contraction force. Data are presented as 
means ± SE 
 
 
Table A.1: Cytokine expression in muscle and serum 
  Sal/Sal GLN/Sal Sal/LPS GLN/LPS 
TNFα     
Serum 0.8 ±.7 2.6 ±1.9 261.2 ±85.4* 347.5 ±192.1* 
Muscle 14.7 ±2.6 12.8 ±5.2 9.0 ±3.8* 7.2 ±2.7* 
IL-6     
Serum 13.5 ±4.7 17.0 ±7.7 542.5 ±470.4* 728.1 ±539* 
Muscle 325.1 ±81.6 336.4 ±67.8 311.8 ±158 160.0 ± 91.8† 
Table A.1: TNFα and IL-6 protein levels in serum and skeletal muscle 2 hours after administration 
of LPS with or without glutamine (GLN). Saline (Sal) was the vehicle control for both LPS 
and GLN. * p<.05 versus corresponding saline group. †p<.05 versus all other groups. 
 
  
92 
 
FIGURE A.2: HSP25 AND HSP70 PROTEIN EXPRESSION 
 
Figure A.2. Changes in skeletal muscle Hsp25 (A) and Hsp70 (B) protein levels 2 hours after 
administration of LPS with or without glutamine (GLN). Saline (Sal) was the vehicle 
control for both LPS and GLN *p<0.05 as compared to sal/sal control. Data are presented 
as means ± SEM.  
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Discussion 
 Inflammatory diseases and acute inflammatory insults are often associated with skeletal 
muscle weakness, either as a result of muscle wasting or a more direct mechanism of contractile 
dysfunction 
141,142,190,150,143,145
. In this study we investigated a potential therapy for these 
conditions, with the design following from the fact that similar effects are seen in animal models of 
endotoxin exposure 
191-193
. Our data confirms the hypothesis that GLN supplementation preserves 
muscle force output during an acute inflammatory insult; the group that received LPS without 
GLN showed a significant, 33% reduction in force as compared to the two saline groups. In 
contrast, concurrent injection of LPS and GLN was associated with no reductions in maximal 
isometric force and a significant reduction in muscle levels of IL-6. Surprisingly, the preservation 
of force with concurrent GLN and LPS administration was not associated with a reduction in 
muscle or serum TNFα. 
 A large body of previous research has found elevated TNFα levels to be correlated with a 
decrease in force production ability in the diaphragm 
159-161,144,162,163
, and GLN administration has 
been shown to reduce circulating TNFα during sepsis 172. As such, a primary hypothesis of the 
current study was that GLN would preserve force under inflammation in skeletal muscle, and this 
would be associated with a reduction in TNFα levels. However, muscle TNF levels were 
significantly lower in the LPS-treated groups, though the absolute levels were very low and it is 
unlikely that the ~2pg/mg reduction caused by GLN had any physiological impact. In perspective, 
previous data from our lab found basal levels of TNFα to be as high as ~75pg/mg 189. Additionally, 
while serum TNFα was elevated by LPS administration as expected, no significant effect on TNFα 
levels was found for GLN supplementation. These findings suggest that GLN’s force-preserving 
properties are downstream of any effects TNFα may have on the muscle. Furthermore, the 
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literature on TNFα and skeletal muscle force is not as definitive as that regarding the diaphragm; 
the studies that have been conducted are not all in agreement on the effects of TNFα. Some show a 
decrease in force 
159
 and others show no effect 
161
. Indeed, the findings of our study support the 
notion that at least circulating TNFα levels do not decrease force in hindlimb skeletal muscle in 
this experimental model. 
 While LPS administration significantly elevated IL-6 levels in the serum, these changes 
were not observed at the muscle level. This is in agreement with previous work that showed LPS-
induced increases in muscle IL-6 mRNA occurred 2 hours post-injection and peaked at ~4 hours 
194
. Further, we have shown that lower doses of LPS are associated with significant increases in 
both skeletal and cardiac muscle 4 hours following LPS injection 
195,189
. Therefore, the expectation 
in this study was that the more rapidly responding serum, not muscle, IL-6 would play a role. 
However, our data shows that muscle IL-6 was significantly reduced in the GLN/LPS group as 
compared to all other groups. Interestingly,  GLN was associated with reductions in IL-6 below 
basal levels, indicating that, in the presence of an inflammatory stressor, GLN is able to reduce IL-
6 levels in muscle, rather than attenuating increased expression. The direct impact of this reduction 
on force production is difficult to determine, as IL-6 has been implicated in chronic muscle 
wasting and atrophy, rather than acute functional decrements 
164-169
. IL-6 has, however, been 
shown to augment acute proteolysis, but only when other inflammatory mediators such as TNFα 
are present 
165
. This property may explain why the saline/LPS group experienced a force 
decrement despite the fact that IL-6 levels were not elevated in comparison to the saline treated 
groups; the saline treated groups did not have the elevated serum TNFα levels necessary for IL-6’s 
augmentation of proteolysis. Conversely, the GLN/LPS group had elevated serum TNFα, and so it 
may have benefited from a reduction in muscle IL-6. 
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 Interestingly, concurrent administration of GLN and LPS was associated with significant 
reductions in Hsp70, but no increase in Hsp70 was seen with the administration of LPS alone. 
While this does not support our hypothesis and is in contrast to the GLN-associated increases in 
Hsp expression shown in non-muscle tissues, it is possible that GLN administration during this 
inflammatory insult significantly reduced the stress experienced by the muscle, thereby attenuating 
expression of the stress protein Hsp70. This is further supported by the finding that at 24 hours 
following concurrent administration of LPS and GLN, Hsp25 was also reduced in skeletal muscle. 
While these findings are in contrast to the literature regarding GLN and Hsp expression in several 
non-muscle tissues 
170,173
, they suggest that the primary role of skeletal muscle in maintaining GLN 
levels in the blood positions it to be uniquely affected by supplementation. Furthermore, the Hsp 
data mirrors the IL-6 findings in that both measures were reduced below baseline levels by GLN 
supplementation, but only in the presence of LPS. These Hsp reductions may be a direct result of 
the IL-6 reductions, as IL-6 has been found to mediate increases in Hsp70 in human skeletal 
muscle
196
 and increases in both Hsp25 and Hsp70 in human hepatoma cells
197
. Therefore, the 
reduced IL-6 protein levels in the GLN/LPS treated mice may have led to a reduced stimulus for 
Hsp expression. 
While the GLN dose utilized in the present study (1g/kg) may not be suitable for long-term 
therapy in humans, it would be a very possible intervention during a more severe and acute 
inflammatory insult such as sepsis.  However, lower doses of GLN may also be effective, as in a 
cecal ligation and puncture (CLP) model of sepsis in rats, a 0.75g/kg dose of GLN given 1 hour 
post-CLP effectively improved clinical outcomes 
172
. Among the outcomes of interest was the 
development of Acute Respiratory Distress Syndrome (ARDS), which was reduced in the GLN-
supplemented animals, and this reduction was associated with lower inflammatory cytokine release 
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and reduced tissue damage in the lungs 
172
. Our novel findings suggest that there may also be a role 
for GLN in diaphragm function during sepsis, as endotoxemia has been shown to decrease 
diaphragm function 
198-200,41
, thus potentially contributing to respiratory distress.  Since the 
diaphragm shares the striated muscle phenotype with the gastrocnemius it could also potentially 
benefit from GLN supplementation through similar mechanisms. 
These results demonstrate that GLN administration has the ability to completely restore 
acute inflammation-induced reductions in muscle force, and that as such it presents a clinically 
relevant intervention for a variety of inflammatory insults. The cytokine and Hsp data indicate that 
the preservation of muscle force by GLN administration is not dependant on a reduction in TNFα 
or an increase in Hsp expression, but rather it was associated with a reduction in muscle IL-6 and 
Hsp70 levels. Additionally, the unique responses of the stress-induced Hsp proteins and IL-6 in 
skeletal muscle indicate that GLN supplementation may play a significant role in reducing the 
stress experienced by skeletal muscles during an acute inflammatory insult.  Clinically, this may 
greatly improve recovery following an inflammatory insult, as skeletal muscle comprises 40-50% 
of body mass and is critical for performing activities of daily living.  
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